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IntroductIon
The hepatitis B virus (HBV) belongs to the family of hepadna viridae and has a diameter 
of 42-47 nm. 1 The virus particle encloses a partially double-stranded DNA genome with 
a length of approximately 3200 base pairs. Within the viral DNA genome four open read-
ing frames (ORFs) can be identified and are termed in analogy of their encoding protein 
S (surface), C (core), P (polymerase) and X (HBx protein). The ORF S contains 3 regions, 
the ore S1, pre S2 and S, which encode for the large, middle and small hepatitis B surface 
glycoproteins depending on the start of the transcription site, respectively. The ORF 
C is responsible for encoding the hepatitis B e-antigen (HBeAg) and the core antigen 
(HBcAg). After the binding of the virus particle to the hepatocyte, the HBV viral genome 
is converted into covalently closed circular DNA (cccDNA) in the hepatocyte nucleus. 
This cccDNA form the key template for pregenomic RNA in the HBV replication cycle 
and acts as a reservoir for the HBV. In the hepatocyte cytoplasm, along with the core and 
polymerase proteins the pregenomic RNA is assembled to virus particles. Sequentially, 
the RNA is reversed transcribed into a HBV-DNA minus strand, which is finally transcribed 
by a HBV DNA polymerase into the HBV DNA plus strand. The formed particle can either 
be excreted via the Golgi apparatus or recycled into the nucleus to form ccc-DNA. 2
As a result of variety in expression of the viral genome, the HBV is divided into 8 
different genotypes, A-H. 3, 4 The HBV genotypes are also characterized by different 
geographical and demographical distribution. Genotype A is predominantly found in 
North-West Europe and North America, whereas genotypes B and C are mostly seen in 
Asian countries. Genotype D is most common in the Mediterranean area. Consequently, 
Caucasians harbor predominantly genotype A and D, while Asians harbor almost exclu-
sively the genotypes B and C. 5, 6
Hepatitis B virus infection is a serious global health problem with more than 350 mil-
lion people suffering from chronic hepatitis B virus infection. Approximately, 15-40% of 
these patients will develop cirrhosis, liver failure or hepatocellular carcinoma (HCC). 7 
Chronic HBV infection accounts for 500,000 to 1.2 million deaths each year and is the 
10th leading cause of death and the 5th most common cause of cancer related deaths. 8-10 
Persistent viral replication is associated with liver disease progression; thus, suppression 
of viral replication is of uttermost importance. Increasing evidence exists suggesting 
that persistent viral replication is a risk factor for the development of cirrhosis and HCC. 
Patients with a viral load of 104-105 copies/ml had an adjusted hazard ratio of 2.5 and 2.3 
for the development of cirrhosis or HCC, respectively, increasing to >5 and >6 for patients 
with over 105 copies/ml. 11, 12 Treatment of active chronic hepatitis B infection prevents 
disease progression. 13 Treatment with immunomodulatory agents, interferon-α or its 
pegylated form, acts mainly by stimulating the immune system and has a modest direct 
antiviral effect. Interferon, a cytokine that affects many processes in the body, causes a 
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considerable amount of side effects. Interferon therapy is effective in approximately one 
third of both HBeAg-positive and HBeAg-negative chronic HBV patients and, in general, 
responders experience long-term inactivation of their chronic infection. 14-16 Another 
treatment option for chronic HBV includes the nucleoside and nucleotide analogues, 
which mainly target the viral polymerase and thereby inhibit viral replication directly. 17 
Due to the high replication rate of the virus (up to 1010-1012 virions a day) and the lack of 
proofreading by reverse transcriptase, the de novo mutation rate is high. In combination 
with selection pressure by antiviral drugs, this may select drug resistant mutants. 18, 19 In 
this review, we discuss the advantages and disadvantages of nucleoside and nucleotide 
analogues for the treatment of chronic HBV. Also the diagnosis and management of 
antiviral resistance to nucleoside and nucleotide analogues is discussed.
LAmIVudIne
Lamivudine (3TC or 2’,3’-dideoxy-3’-thiacytidine) is the first registered nucleoside 
analogue for the treatment of chronic HBV. It is a cytosine analogue, which has to be 
phosphorylated to its active metabolite. It directly inhibits the viral polymerase by com-
peting with natural thriphosphates for incorporation into the viral DNA by the viral DNA 
polymerase, thereby terminating chain elongation. 20
Lamivudine proved to be a very well tolerated drug with an excellent safety profile 
comparable to placebo. With prolongation of therapy, the safety profile does not 
change. 21-25
Hbeag positive disease
Lamivudine is a strong inhibitor of viral replication and a decline of 5.40 log10 copies/
ml is feasible after one year of treatment. Due to the generally high viral load in HBeAg 
positive subjects, 36% of the patients will reach a load below the lower limit of detection 
(LLD 300 copies/ml). Thus, many patients will still experience considerable viral replica-
tion as reflected by a mean HBV DNA of about 104 copies/ml. Furthermore, there is a 
large variation in viral loads greater than 104 copies/ml in many patients after 1 year 
of treatment. Maximum efficacy is reached between weeks 24 and 36 and the viral 
response weakens thereafter. 21, 23
ALT normalizes in 44-72% of the patients after one year of treatment. 21-23 As a reflection 
of viral suppression and decline in ALT levels, necro-inflammation improves in 52-64% 
of patients. No improvement is observed in 34-42% of patients; of these patients, 7-10% 
experienced worsening inflammation with paired biopsies. 21-23, 26 The fibrosis score 
improves in 35%, remains unchanged in 55% and worsens in 10% of patients. 23 Loss of 
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HBeAg and the seroconversion to anti-HBe as a sign of partial immunological control 
occurs in 17-22%. 21-23, 26 Loss of HBsAg is only seen in sporadic cases.
With prolonged treatment, some patients have a sustained on-treatment response 
while in others, lamivudine loses its efficacy due to the emergence of drug resistant 
mutants. It is hard to estimate from the published mean HBV DNA data whether the 
viral load declines further if treatment is prolonged after one year due to the rebound in 
HBV-DNA levels as a consequence of resistance. In a single cohort study, prolongation 
of treatment showed an increase in the estimated Kaplan-Meier HBeAg seroconversion 
rates from 27% to 40% to 47% and to 50% at years 2, 3, 4 and 5 respectively. 25, 27-29
Discontinuation of lamivudine resulted in an increase in HBV DNA levels for the entire 
group. 21 In a long-term follow-up-up study of patients with HBeAg seroconversion dur-
ing the phase II and III trials, the duration of response was investigated. The median time 
from the end of the study to enrolment in the follow-up study was 4.3 (0-27) months. At 
the start of follow-up, 72% had undetectable HBV DNA levels (LLD 7.0 x105 copies/ml) 
and this percentage remained 72% at the end of follow-up (median duration 36.6 (4.8-
45.6) months). ALT responses diminished as the percentage of patients with normal ALT 
declined from 73% at baseline to 63% at the end of follow-up. HBeAg seroconversion 
was sustained in 77% of subjects. 30 The durability of sustained response rates may be 
affected by the duration of treatment after HBeAg seroconversion. In a Korean study, 
patients who received up to two months of therapy after HBeAg seroconversion had a 
higher relapse rate (74%) compared with those receiving treatment for at least 4 months 
(37%) of lamivudine after HBeAg seroconversion at year 2 of follow-up. 31 In patients in 
which HBV DNA (hybridization assay, LLD 106 copies/ml) and HBeAg were persistently 
negative for at least 24 months during lamivudine therapy, cumulative reappearance 
rates of HBV DNA after cessation of therapy were 15%, 21% and 31% at 6, 12 and 24 
months of follow-up. 32 Cumulative reappearance rates of HBeAg were 11%, 13% and 
16%. These data suggest that long-term administration of lamivudine might enhance 
the durability of HBeAg seroconversion. Therefore, it is recommended to continue 
treatment for at least 3-4 months after HBeAg seroconversion. Viral load, at the time 
of discontinuation, is a predictor for sustained response. Patients with a low viral load 
(<200 copies/ml) had significantly lower relapse rates (reappearance of HBV DNA (>5.0 
x105 copies/ml and/or HBeAg) (37%) compared to those with a viral load ≥103 copies/ml 
(73%) at 2 year follow-up. 33
Resistance is caused by mutations in the viral DNA polymerase (YMDD region) and 
develops as early as six months after treatment; after one year, 14-32% were lamivudine 
refractory. 21, 22 With longer treatment duration, the incidence of YMDD mutants increased 
to 38%, 53%, 67% and 69% at 2, 3, 4 and 5 years respectively. 25, 28, 29, 34 Over 90% of pa-
tients developing resistance experience rebounds in HBV-DNA and ALT levels, although 
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viral load and ALT level remain significantly lower compared to baseline. 21, 28, 35 In some 
patients, the emergence of resistance resulted in reversal of their initial histological 
improvement. 28, 36 A surge of HBV DNA followed by a hepatitis flare with serum ALT >5 
upper limit of normal (ULN) occurred in approximately 40% of patients within 1 year 
after the development of resistance and increased up to >80% by year 5. 37, 38 In addi-
tion, severe hepatitis with hepatic decompensation or even fatality may occur, 37, 39 After 
the development of resistance, continuation of lamivudine does not seem beneficial. 
Hepatic flares and decompensation occurred in 67% and 11%, respectively, in patients 
continuing lamivudine for 12 months. In patients who discontinued lamivudine, hepatic 
flares and decompensation occurred in 54% and 7%, respectively. In addition, HBV DNA 
levels increased in 73% of patients in the continuation arm compared to 33% in the 
discontinued group.. HBeAg seroconverion occurred in 19% of the group continuing 
lamivudine and 35% of the patients discontinuing lamivudine. 34
Hbeag negative disease
Treatment of nucleoside naïve HBeAg negative subjects with 100 mg lamivudine once 
daily resulted in a rapid and strong decline during the first 24 weeks of treatment and 
a much slower decline until 36 weeks after which there was a slight increase in viral 
load. After 48 weeks of treatment, the viral load declined by 4.2-4.5 log10 copies/ml. 
16, 24 
In one study, 89% of the subjects had a viral load less than 7.0 x105 copies/ml and 72% 
had undetectable HBV DNA levels (LLD 300 copies/ml). 24 In another study, 85% had a 
viral load below 2.0 x104 copies/ml and undetectable levels as determined by PCR (LLD 
400 copies/ml) in 73%. 16 ALT levels normalized during treatment; at week 48, 71-73% 
had normal ALT levels. 16, 24 Smaller open labeled studies reported ALT normalization in 
60-96% of cases after 12 months of treatment. 40-43 Histological improvement, defined 
as improvement by at least two points in the Knodell necroinflammatory score with no 
worsening in the Knodell fibrosis score, occurred in 61%. There was no histological im-
provement in 26% of the patients. Despite improvement and ALT normalization in most 
patients, the mean Knodell necroinflammatory score was 4.6 at the end of treatment; 
there was still some inflammation in many patients at microscopic level. 24 The Ishak 
fibrosis score improved in 38%. 44 In patients with severe fibrosis at baseline, the Ishak 
fibrosis score improved (≥1 point) in 53%, remained unchanged in 18% and worsened 
in 5%. 45 Continuation of treatment does not result in significantly improved treatment 
outcomes as the percentage of PCR negative subjects increased from 72% to 77% and 
ALT normalization increased from 71% to 84% after 96 weeks of treatment. 44 Other stud-
ies found a sustained response with prolonged treatment. HBV DNA negativity (<7.0 
x105 copies/ml) was 89% after 1 year and 75% after 2 years. ALT levels were normal in 
81% after 1 year and in 69% after 2 years of continuous treatment. 46 Others experienced 
loss of efficacy with prolonged treatment with the percentages of HBV DNA negativ-
Introduction 13
ity dropping by 21-31% between month 12 and 24. 40, 47, 48 ALT responses (normal ALT) 
declined over time being 96% at month 12, 59.5% at month 24 and 42.5% with over 30 
months of treatment. 40
Discontinuation of therapy frequently results in loss of response. After 6 months of 
follow-up, HBV DNA suppression was lost in most patients as the percentage of PCR 
negativity (LLD 400 copies/ml) decreased from 73% to 7% and the subjects with HBV 
DNA levels <2.0 x105 copies/ml from 85% to 29%. ALT levels increased and 29% lost 
their biochemical response and after 6 months 44% had normal ALT levels. 16 A study 
with a longer duration of follow-up after treatment cessation showed an 87% relapse 
rate in initial responders (HBV DNA <1.4 106 copies/ml and normal ALT) and a sustained 
response in 15%. 49
Lamivudine resistance emerged in 18-27% after 1 year and increased over time to 
44% at year 2 and 60% after 4 years of treatment. 16, 40, 46, 50 The data on the clinical impact 
of YMDD mutation are controversial. Some studies suggest little impact on therapeutic 
response. 46, 50 Others report increases in serum HBV DNA levels and ALT and loss of 
histological response in almost all patients. 40, 48, 51, 52 The emergence of resistance can be 
associated with clinical significant hepatitis. 40, 52
AdeFoVIr
Adefovir dipivoxil (PMEA or 9-(2-(phosphonomethoxyl)ethyl)-adenine) is an oral prodrug 
of adefovir which already contains a phosphate group and requires only a final phos-
phorylation step before competing for integration into the forming HBV DNA strand 
resulting in chain termination. The 10 mg dose used for the treatment proved to be safe 
acutely and chronically. Treatment with higher doses of adefovir increased the risk of 
nephrotoxicity. 53, 54 Nephrotoxicity is infrequent with the 10 mg dose but dose reduction 
is still required with declining kidney function. 55
Hbeag positive disease
Treatment with 10 mg adefovir once daily for 48-52 weeks resulted in a 3.52-4.5 log10 
copy decline in viral load and 28-36% reached PCR negativity (LLD 300-400 copies/
ml). 53, 56 Quantitative viral decline of 4 quartiles ((25%) of patients) could be identified; 
>4.91 log10 reduction, 3.52-4.91, 2.22-3.51 and <2.22 log10 reduction after 48 weeks of 
treatment. 57 HBeAg loss occurred in 13-24% of patients and 8-12% had HBeAg serocon-
version at 1 year.
ALT levels declined and, at the end of treatment, 48-79% of ALT levels normalized. 
The decline in viral load and ALT was also reflected in the improvement of histology. 
Improvement, defined as a reduction of at least two points of the Knodell necroinflam-
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matory score with no concurrent worsening of the Knodell fibrosis score, occurred in 
53% of the patients. The necroinflammatory score improved in 71%, did not change in 
15% and worsened in 13%. Fibrosis improved in 41%, remained unchanged in 45% and 
worsened in 14%. 53
A study investigating the efficacy of prolonged treatment was hampered to some 
extent, as most patients received ≥1 dose of placebo in the second year due to a dose 
allocation error. As the length of study follow-up varied, Kaplan-Meier estimates were 
used. With prolonged treatment, the percentage of patients with a viral load below 103 
copies/ml increased from 28% at year 1 to 45% and 56% at years 2 and 3, respectively. 
ALT levels became normal in 48%, 71% and 81% after 1, 2 and 3 years of treatment, 
respectively. Rates of HBeAg-loss increased to 42% and 52% and HBeAg seroconversion 
rates increased to 29% and 43% at year 2 and 3, respectively. 58 A study continuing treat-
ment up to 2 years showed an increase in viral reduction from -4.5 to -5.0 log10 copies/
ml, increase in PCR-negativity (LLD 300 copies/ml) from 28% to 42%, but the percentage 
of ALT normalization remained unchanged (79% to 78%). The percentage of HBe-loss 
increased from 13% to 19% and the percentage of patients with HBe-loss and develop-
ment of antibodies increased to 15%. 56
In most patients, discontinuation of treatment results in a rapid viral rebound with 
HBV DNA levels returning to baseline. The increase in viral replication is accompanied 
by a loss of ALT response and, after 12 weeks of follow-up, 21% had normal ALT levels. 56 
However, patients with HBeAg seroconversion had a sustained response in 91% after a 
median follow-up of 143 months (rang 13-245) with a median HBV DNA of 103 copies/
ml and a viral load <103 copies/ml in 93%. Nine percent lost their initial HBeAg response 
and these patients had a shorter duration of adefovir treatment after HBeAg serocon-
version, suggesting adefovir should be continued for several months after the HBeAg 
seroconversion. 59
The occurrence of resistance is low. No adefovir related mutations were found after 
1 year of treatment and after two years of treatment resistance was found in 1.3-3%. 
Little research exists investigating the course of liver disease after the development of 
resistance, but increases in serum HBV DNA and ALT levels occur and there is also the 
possibility of severe hepatitis and liver decompensation. 60-62
Hbeag negative disease
Treatment of adefovir for 48 weeks in HBeAg negative subjects resulted in a 3.85-3.91 
log10 copies/ml reduction in HBV DNA levels, undetectable HBV DNA levels (LLD 400 cop-
ies/ml) in 51% and ALT normalization in 72-80%. 55, 63 Histological improvement, defined 
as improvement by at least two points in the Knodell necroinflammatory score with no 
worsening in the Knodell fibrosis score, occurred in 64% and the Knodell necroinflamma-
tory score improved from 8.0 points with a median of 3 points. Necroinflammatory scores 
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improved in 80%, remained unchanged in 17% and worsened in 3% of patients. The Ishak 
fibrosis score improved in 48%, remained unchanged in 47% and worsened in 4%. 63
Continuation of treatment up to 2 years, did not lead to much decline in viral load but 
consolidated the response to adefovir, as 71-75% of the patients had a viral load below 
103 copies/ml and 73-79% experienced ALT normalization. Long-term treatment up to 
5 years resulted in a viral load below 103 copies/ml in 78-79% at year 3, 65-68% at year 
4 and 67% after 5 years of continuous treatment. ALT levels were normal in 69-78% at 3 
years, 70-75% at 4 years and 69% after 5 years. 55
Improvement in necroinflammatory scores compared to baseline were also sustained 
with long term treatment with adefovir. Over 80% of patients showed improvement, 
with a median decline of necroinflammatory scores of 4.5 and 5.0 after 4 and 5 years 
of treatment, respectively. Fibrosis improved in time during treatment and 55% had 
improved Ishak fibrosis scores after 4 years of treatment and 71% had improved scores 
at year 5. The percentage with worsening necroinflammatory scores or fibrosis score was 
about 5% with long-term therapy. 64
Discontinuation of therapy after 1 year resulted in a rapid loss of response. HBV DNA 
levels increased from 103 copies/ml to over 105 copies/ml, but did not return to baseline 
values. About 50% lost their ALT response and after a year of follow-up only 30% had 
normal ALT levels. 55 Even after 4-5 years of treatment, response is not sustained in the 
majority of patients as only 30% of patients had a viral load below 104 copies/ml and 
56% had HBV DNA levels of over 105 copies/ml after 15 months of follow-up in patients 
with a complete response during treatment. ALT levels increased transiently followed 
by sustained normal levels in 36.4%, were elevated in 33.3% at the end of follow-up and 
30.3% had normal ALT levels.
Resistance to adefovir was not detected after 1 year of treatment. With continuous 
treatment, resistance increased to 3%, 11%, 18% and 28% at year 2, 3, 4 and 5, respec-
tively. 65 Little is known about the course of disease after the development of resistance, 
but increases in serum HBV DNA and elevation of serum ALT occur. Additionally, severe 
hepatitis and decompensation have been reported. 60-62
entecAVIr
Entecavir (ETV) is a guanosine analogue and has to be metabolized within hepatocytes 
to its acitive metabolite entecavir-triphosphate. It acts by directly inhibiting three of 
the four catalytic activities of the viral polymerase: priming, reverse transcription and 
DNA-dependent DNA synthesis. Toxicology studies, as well as clinical studies, revealed 
that entecavir is a safe drug with a safety profile comparable to lamivudine. Safety is 
preserved with extended treatment.
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Hbeag positive disease
Treatment of nucleoside/nucleotide naïve HBeAg positive subjects with 0.5 mg once 
daily resulted in a rapid decline in viral load during the first 24 weeks and a slower but 
continuous decline to week 48, at which the viral load declined to a median of 6.98 log10 
copies/ml. PCR negativity occurred in 67% of patients and 91% experienced viral loads 
<7.0x105 copies/ml. ALT levels normalized in 68% of patients. Histological improvement, 
defined as improvement by at least two points in the Knodell necroinflammatory score 
with no worsening in the Knodell fibrosis score, occurred in 72%. In 8%, the Ishak fibrosis 
score worsened and the Knodell necroinflammatory score declined from 8.2 to 4.4.
Continuation of entecavir in patients with detectable HBV DNA beyond 48 weeks 
resulted in a continuous decline in viral load and PCR-negativity increased to 81% after 
96 weeks of treatment. 66, 67
Loss of HBeAg occurred in 22% after 48 weeks of treatment and 21% of patients expe-
rienced HBeAg seroconversion. In HBeAg-positive patients without continuing therapy, 
an additional 10% experienced HBeAg seroconversion resulting in an overall HBeAg 
seroconversion rate of 31% after two years of therapy.
Discontinuation of therapy in responders to entecavir (HBeAg loss, HBV DNA <7.0x105 
copies/ml and ALT<1.25 upper limit normal) resulted in a sustained response in 73% 
of patients. HBeAg loss and load below 7.0x105 copies/ml was sustained in 82% of 
patients.
Resistance to entecavir did not occur during 96 weeks of treatment. A total of 12 viral 
rebounds (≥ 1 log increase from nadir) were documented during clinical trials, but no 
entecavir-associated mutations could be detected. In addition, no entecavir mutations 
were identified in patients failing to PCRachieve negativity. In nucleoside-naïve patients, 
entecavir proved to have a very high genetic barrier to resistance. 67
Hbeag negative disease
Treatment of nucleoside treatment naïve, HBeAg negative subjects with 0.5 mg ente-
cavir once daily resulted in a rapid viral decline during the first 24 weeks, after which the 
majority of patients were PCR negative (LLD 300 copies/ml) and continued to decline 
to a total of 5.0 log10 copies/ml after 48 weeks of treatment. At this point 90% were PCR 
negative. ALT levels normalized in 78% of patients. Histological improvement, defined 
as improvement by at least two points in the Knodell necroinflammatory score, with 
no worsening in the Knodell fibrosis score occurred in 70% and Ishak fibrosis scores 
improved in 36%. In 19%, liver histology did not improve. In spite of this improvement, 
the mean Knodell necroinflammatory score at week 48 was 4.2, indicating some patients 
still had liver inflammation at a microscopic level.
Treatment discontinuation in patients classified as responders (HBV DNA <7.0x105 
copies/ml and ALT <1.25 ULN) resulted in a sustained response in 48% of patients after 
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24 weeks of follow-up. Twelve percent experienced an increase in ALT to over 5 times the 
ULN and 8% experienced a severe flare (ALT >10 times ULN) after discontinuation. 24
In nucleoside-naïve patients, resistance did not occur during the 96-week study pe-
riod. Six patients experienced viral rebound (>1 log10 copies/ml increase from nadir), but 
resistance testing revealed no entecavir-associated mutations.
mAnAgement oF treAtment FAILures
A distinction has to be made in patients failing therapy due to the emergence of drug 
resistant mutants, or those failing treatment for other reasons.
Definitions have been formulated in order to distinguish the cause of failure. Primary 
treatment failure is defined as < 1 log10 IU/l (=1.78 log10 copies/ml) decrease in HBV DNA 
after 12 weeks of treatment. Several factors may contribute; non-compliance, inefficient 
conversion from the prodrug to its active metabolite, inadequate phosphorylation within 
the hepatocytes or under dosing of the drug. Under-dosing is particularly an issue with 
10 mg adefovir which was selected for safety reasons to prevent nephrotoxicity as docu-
mented with the 30 mg dose. 53 However, resistance cannot be ruled out completely as 
some nucleoside or nucleotide patients are already resistant to the drug. 68, 69
Secondary treatment failure is defined as an increase of >1 log10 IU/l after an initial 
decrease of 1 log10 IU/l in HBV DNA as confirmed by two consecutive measurements at a 
1-month interval. Factors to be considered are non-compliance and resistance.
Little is known about the causes of treatment failure in non-drug resistant patients. It 
is not known why some patients experience excellent viral suppression and others sub-
optimal suppression. There are predictors of treatment response at baseline: high serum 
aminotransferase (>5x ULN) levels, high degree of necroinflammatory activity and low 
serum HBV DNA. 70, 71 A high viral load is probably one of the reasons why treatment 
outcomes on viral suppression are less effective in HBeAg-positive subjects compared 
to HBeAg-negative subjects.
Because viral factors, as well as individual factors, play a role in treatment outcomes, 
it is difficult to assess the best treatment option for non-responders. In theory, all other 
nucleoside or nucleotide analogues should be effective. Very little clinical data are avail-
able to prove this. Drug sensitivity testing in cell cultures is of little value as it takes only 
viral factors into account. The sensitivity of wild-type virus is measured and clinical data 
about the potency is already known from clinical trials. Presuming randomization leads 
to an equal distribution of individual factors, more potent drugs are expected to sup-
press viral replication in subjects failing treatment. Entecavir is a more potent drug than 
lamivudine in the laboratory setting and proved its higher potency in clinical trial where 
more entecavir treated subjects had response. 23, 24 In adefovir failures, the more potent 
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drug tenofovir proved effective in treating this patients. 72 Also, the addition of another 
drug could be feasible. In vitro testing demonstrated the combination of adefovir with 
an L-nucleoside (lamivudine, telbuvidine, emtricitabine) and exerted additive antiviral 
effects. 73 Large studies are needed to determine treatment efficacies of antiviral agents 
or their combination in non-drug resistant subjects failing antiviral treatment.
rIsk FActors For drug resIstAnce
Risk factors for the development of lamivudine resistance are: prior course of lamivudine, 
duration of lamivudine therapy, high body weight and body mass index, male sex, high 
baseline HBV DNA, insufficient HBV DNA suppression and elevated ALT levels during 
treatment. 35, 74, 75 Risk factors for the development of adefovir resistance are: lamivudine 
resistance at start of treatment, high baseline viral load, overlap <1 month of lamivudine 
+ adefovir in case of lamivudine resistance, insufficient HBV DNA suppression during 
treatment. 76-78 Predictors for entecavir resistance are: lamivudine resistance and subop-
timal suppression of HBV DNA on treatment. 79 Persistent on-treatment viral replication 
is a major factor for the development of resistance and this has been shown best in 
lamivudine treated subjects. A study showed that patients with serum HBV DNA of 
>103 copies/ml after 6 months had a 63% chance of developing resistance. 75 In another 
study in 24 lamivudine treated patients for > 1 year, none of the patients with a nadir 
HBV DNA <50 copies/ml developed resistance, 2 out of 5 patients had a nadir viral load 
between 50-300 copies/ml and all 11 patients with a nadir viral load >300 copies/ml 
developed resistance. 74 A load of 105 copies/ml after 48 weeks of treatment is predictive 
for the development of adefovir resistance. However, as resistance is rare, larger groups 
of adefovir resistant patients have to be studied in order to identify risk factors. 78 About 
entcavir, even less is known. Viral load during treatment seems to play a role as 81% of 
the patients developing resistance had a nadir viral load above 104 copies/ml. 79
detectIon oF drug resIstAnce
Clinically, antiviral resistance has to be suspected when a virological or biochemical 
breakthrough occurs. A virological breakthrough is not strictly defined, but it is generally 
agreed to be a 1 log10 increase in viral load either in copies/ml or as IU/l after an initial 
response in compliant patients. 80-82 The use of sensitive PCR techniques is advised to 
monitor the viral load during treatment. The response can be assessed more accurately 
and an increase in viral load is detected earlier because of the lower level of detection 
(see fig. 1).
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Biochemical breakthrough is usually defined as an ALT level >1.5 ULN during continu-
ing treatment in patients who initially had normal ALT levels. 81, 82 In the majority of cases, 
a virological breakthrough precedes a biochemical breakthrough and the time lapse 
may vary from weeks to months. 83 Compliance should be confirmed, as it may be a more 
common cause of treatment failure as expected. In case of non-compliance, this subject 
has to be reinforced and follow-up is necessary to determine whether the patient is 
again responsive to therapy. By using the sensitive tests, the chance of detecting viral 
breakthrough during the time laps to biochemical breakthrough is increased.
Genotypic testing provides information such as which mutations have arisen during 
treatment and whether these mutations may correlate with the clinical phenotype. This 
information is useful when determining the treatment strategy, as there might be cross-
resistance to other antiviral agents. Resistance testing can be done by direct sequencing 
of the HBV polymerase/reverse transcriptase gene or reverse hybridization-based assays, 
such as the line probe assay. Direct sequencing is able to detect new mutations while 
the line probe assay is designed to interrogate for a selected known mutation associated 
with drug resistance. The major advantage of the line probe assay is that it is able to 
detect selected mutations earlier than sequencing techniques, and in patients with low 
levels of serum HBV DNA. 84, 85
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Figure 1. HBV DNA and ALT levels after the initiation of antiviral therapy with nucleos(t)ide analogues in 
chronic hepatitis B.
After starting therapy, there is a decline in viral load with a concurrent drop in ALT levels afterwards. 
When resistance develops, there is a rise in HBV DNA. Subsequently, there is an increase in ALT levels. With 
sensitive HBV DNA assays, a rise in viral load can be observed soon after the development of resistance. 
When less sensitive tests are used or only ALT levels are measured to detect antiviral resistance, there is 
less time to switch to other nucleos(t)ide analogues to manage the developed resistance and to prevent 
an ALT flare.
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mAnAgement oF drug resIstAnce
lamivudine resistance
Switching to adefovir dipivoxil is an effective treatment for lamivudine resistant chronic 
hepatitis B and is able to suppress viral load by 4 log10 copies/ml after 48 weeks of 
treatment. 26% of patients had a viral load below 103 copies/ml (see table 1). 86 There is 
controversial data on the addition of adefovir to continuing lamivudine. It seems that 
there is no benefit in terms of viral suppression for adefovir monotherapy compared to 
adefovir + lamivudine combination therapy as declines in viral loads are similar. 86, 87 Com-
bination therapy of lamivudine and adefovir resulted in negative HBV DNA by PCR assay 
in 20% (LLD 200 copies/ml), below 103 copies/ml in 35% of HBeAg positive patients, PCR 
negativity in 57% (LLD 400 copies/ml) and a viral load below 2.0 x103 copies/ml in 78% 
of HBeAg negative patients at week 48. 86-89 Lamivudine should at least be continued 
for 2-3 months after initiation of adefovir as this overlap may prevent the emergence of 
adefovir resistance. 76 The time of initiation of therapy influences treatment outcomes. 
Fewer patients with phenotypic resistance (HBV DNA >106 copies/ml and elevated ALT) 
responded to treatment compared to the patients with genotypic resistance (HBV-DNA 
104-106 copies/ml) at the time of addition of adefovir to lamivudine. Response in the 
former was also slower. 88 This emphasizes the importance of regular HBV DNA testing, 
with the use of sensitive tests.
Although adefovir is effective, in lamivudine refractory patients, there is some degree 
of cross-resistance. Patients who switched to adefovir monotherapy had a higher rate of 
resistance to adefovir (up to 19% after one year of treatment). 76, 90
Lamivudine and adefovir combination therapy may result in lower resistance rates to 
adefovir. As lamivudine suppresses the adefovir resistant mutants, adefovir resistance 
is lower in patients receiving combination treatment compared to those discontinuing 
lamivudine. 76, 91
Lamivudine resistance confers a dose-dependent cross-resistance to entecavir in a 
cell culture model; however, lamivudine refractory strains remain sensitive to entecavir. 
Treatment outcomes of lamivudine resistant patients with 1 mg entecavir once daily 
were less compared to the nucleoside naïve patients and resulted in a decline of 5.1 
Lamividine Adefovir Entecavir Tenofovir
Lamivudine-resistant R S S# S
Adefovir-resistant S R S S
Entecavir-resistant R S R S
table 1. Management of resistance and summary of cross-resistance profiles.
R= resistant, S= sensitive.
 #Entecavir remains sensitive to lamivudine resistant strains, but the sensitivity is decreased.
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log10 copies/ml and PCR negativity (LLD) in 21% of patients at week 48. ALT normal-
ized in 75% of patients and histological necroinflammatory scores improved in 55% of 
patients. In addition, 34% of patients experienced improvement of fibrosis scores. 92 With 
prolonged treatment in HBeAg negative lamivudine refractory patients up to 96 weeks, 
30% of patients were PCR-negative (LLD 300 copies/ml), 85% had normal ALT levels and 
HBeAg seroconversion was observed in 16% of patients. 93 Entecavir requires multiple 
mutations and therefore has a high barrier to resistance. Entecavir resistance emerges 
after additional mutations in lamivudine resistant strains. 94 After 1 year of entecavir, 1% 
of lamivudine-resistant patients were resistant to entecavir which increased to 9% after 
two years. 79
Tenofovir disoproxil fumaraat, an oral prodrug of tenofovir, is licensed for the treat-
ment of HIV and possesses potent activity against lamivudine resistant HBV and has 
no cross-resistance with lamivudine resistance. 95-97 Results look very promising but all 
studies were very small and the drug has to be studied in larger groups.
adefovir resistance
In vitro, adefovir resistant mutants are susceptible to lamivudine and might therefore 
be used to treat adefovir resistance (see table 1). 98 However, little data are available 
on this treatment option. 62, 99 The effect of adefovir associated mutations on long-term 
lamivudine treatment is unknown and no data is available on lamivudine + adefovir 
combination therapy. Entecavir and tenofovir have been proven to be effective for ad-
efovir resistant mutants, both in vitro and in vivo, as detailed in a number of published 
case reports. 62, 72, 98, 100 Larger studies are needed to study different treatment options for 
patients with adefovir resistance, the same counts for patients resistant to both adefovir 
and lamivudine.
entecavir resistance
Entecavir resistance is highly cross-resistant with lamivudine as entecavir resistance 
requires lamivudine resistance (see table 1). 94 These mutant strains are sensitive to 
adefovir in vitro and clinical treatment with adefovir resulted in viral load declines. 94, 101
dIscussIon
Over the years, immense progress has been made in the understanding, as well as the 
treatment of chronic hepatitis B. Most patients with chronic hepatitis B can be treated 
adequately and as the morbidity and mortality are fairly high especially, in patients 
with cirrhosis, treatment should be initiated when appropriate. As the field of hepa-
titis B quickly evolves, the recommendations for the initiation and type of treatment 
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changes. In the coming years, more antiviral agents will be registered for the treatment 
of chronic hepatitis B. This will extend the arsenal of agents. This will probably result in 
better treatment options, but on the other hand, treatment may become more complex. 
Specifically, resistance issues will be challenging. Fortunately, the resistance rate of 
some antivirals is relatively low, but due the low incidence, it is hard to study resistance 
because enrolling large groups of patients will be necessary. In vitro testing provides 
information on the level of cross-resistance and this work should ideally be done for 
every new mutation found. Also, this work has to be extended to multi-resistant strains, 
which will emerge with the use of multiple drugs either as sequential monotherapy 
and combination therapy. Clinical treatment options for resistant strains will have to be 
evaluated. Although adefovir has been used clinically for several years and large trials 
with extended treatment durations have been performed in which numerous people 
developed resistance, very little data are available about the management of adefovir 
resistance. The same counts for entecavir, but very few resistant cases have been identi-
fied thus far. More studies are needed to investigate the basic mechanisms of treatment 
of non-responders, especially those caused by means other than drug resistance. Some 
patients will not respond to treatment. The factors involved should be more closely 
studied, as well as, the response to other agents. We may be on the verge of a change in 
the treatment of chronic hepatitis B.
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In the early days of chronic hepatitis B treatment prospects of patients were grim. No 
effective therapy was available and liver transplantation was the only option for patients 
who progressed to end-stage liver disease. To worsen matters, HBV infection soon 
became a contraindication for transplantation as survival was poor due to re-infection 
of the transplant liver, followed by an aggressive course leading to graft failure in a 
short time. With the introduction of HBIg therapy post-transplantation recurrence rates 
dropped and survival increased. This resulted in acceptation of HBV infected patients in 
the transplant programs again. In the nineties the only treatment available for chronic 
HBV was interferon. Although many different interferon regimens were explored, treat-
ment results were limited with a response in about one third of patients. In addition the 
therapy was associated with multiple side effects and required thrice weekly injection. 
Relapse after discontinuation was frequent. Retreatment with interferon yielded even 
lower success rates. A new era started with the introduction of the oral nucleoside 
analogues.
With Lamivudine treatment it was possible to control HBV disease in the majority of 
patients, probably even increasing survival. But optimism was short lived as it soon 
turned out the resistance barrier of lamivudine was low, resulting in resistance in up to 
two third to three quarter of patients. Resistance was often accompanied by relapse of 
viral replication and liver inflammation and thus to progression of disease. Sometimes 
the hepatic flare after relapse leads to decompensation or even death. New drugs for 
the treatment of HBV came on the market with increasingly shorter intervals. Treatment 
with PEG-interferon-α improved sustainability of response with much lower side ef-
fects during treatment. New nucleosides and nucleotides are more potent and have a 
higher barrier to resistance. However, treatment is far from perfect. Only a minority of 
patients is cured by interferon treatment, which is not likely to happen with nucleoside/
nucleotide treatment. Thus many patients need life-long monitoring and/or treatment. 
With the availability of several treatment options it became harder to determine the 
best treatment for the individual patients. In the early days the choice was simple, as 
little was known about the prognostic factors for treatment outcome and options were 
limited. Another challenge has emerged in the form of treatment experienced patients, 
who failed prior therapy as a result of non-response to treatment or development of re-
sistance. The best for the patient is patient tailored treatment taking in account variables 
known to influence treatment outcome.
The question is: “Is patient tailored treatment feasible”?
In this thesis we explore the possibility of patient tailored treatment by reviewing the 
literature and by research on treatment outcomes in patients with hepatitis B virus infec-
tion to add and understand some of the variables influencing treatment outcome.
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AIms oF tHe study:
1. To examine the response to PEG-interferon-α in lamivudine experienced patients 
harbouring mutations in the YMDD-motif associated with resistance to lamivudine.
2. To describe the development of entecavir resistance in a treatment experienced 
patient
3. To determine treatment outcomes in patients switched from tenofovir to adefovir.
4. To explore the response to adefovir in an open population, reflecting daily practice. 
Outcomes, predictors for response and resistance.
5. To investigate the feasibility of discontinuing HBIg treatment in patients transplanted 
for acute fulminant hepatitis B virus infection.
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ABstrAct
Objective: To determine the response to pegylated interferon-α treatment of HBeAg-
positive hepatitis B patients with proven lamivudine resistance.
Methods: Sixteen HBeAg-positive HBV patients with YMDD mutations were treated with 
pegylated interferon. Median treatment duration was 52 weeks (range 20–53), with a 
26-week follow up.
Results: Two of 16 (12.5%) patients seroconverted to HBeAg negative and achieved sus-
tained virological (HBV-DNA levels below 10log 5 copies/ml) together with biochemical 
(normalization of serum ALT levels) responses. Compared with the strong signal in all 
other patients, only these two patients had a faint signal in the lamivudine resistance 
assay. For all patients, the median viral load decreased from 10log 9.4 to 7.9 copies/ml 
(p=0.001) during treatment but rebounded to a median of 10log 8.7 copies/ml after 
treatment cessation. Similarly, elevated median ALT levels at baseline decreased with 
treatment but rebounded after the end of treatment.
Conclusion: In the largest cohort study to date, pegylated interferon-α therapy showed 
marginal efficacy in the presence of lamivudine resistance but such therapy may be ben-
eficial in patients with only small amounts of mutant virus. In our opinion, an analysis 
of the patient subgroup harbouring an YMDD-mutation should be included in all future 
studies of pegylated interferon-α in chronic hepatitis B.
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IntroductIon
Although 350–400 million people worldwide are affected by hepatitis B, to date, treat-
ment for patients is frequently unsuccessful. Chronic hepatitis B is an immunological-
based liver disorder, and there is increasing evidence that only a complete and vigorous 
HBV-specific immune response can achieve control and elimination of the virus, pre-
venting disease progression.1 The subgroup of HBeAg-positive hepatitis B patients with 
proven lamivudine resistance are little studied, and existing studies are often hampered 
by their extent and design, which makes it difficult to draw definitive conclusions about 
the optimal treatment for this group. 2-5 In the study reported here, which is the largest 
cohort study to date, we investigate the response of HBeAg-positive hepatitis B patients 
with proven lamivudine resistance to pegylated interferon-α.
The nucleoside analogue lamivudine is an effective inhibitor of viral DNA polymerase. 
It suppresses replication of HBV, improving transaminase levels and liver histology and 
enhancing the loss of hepatitis B e antigen (HBeAg).6, 7 However, sustained response after 
discontinuation of treatment occurs in only 10–15% of lamivudine-treated patients.8 An-
other drawback is the emergence of mutations, in the tyrosine-methionine-aspartate-
aspartate (YMDD-motif ) of the viral polymerase, which are associated with resistance.9 
Mutations sometimes arise as little as six months after initiation of treatment with a 
resistance rate of 15–30% after one year, increasing to approximately 60–70% after four 
years of continuous treatment. 5, 6, 7, 10-13 Some patients who experience virological break-
through may develop acute exacerbation, leading to liver decompensation and death.9
European guidelines recommend pegylated interferon-α as first-line treatment for both 
HBeAg-positive and -negative patients 13 but there remain several unanswered questions 
related to its uptake as a panacea treatment for hepatitis B. There is conflicting evidence 
on the effect lamivudine resistance, caused by mutations in the YMDD-motif, on the 
outcome of pegylated interferon-α therapy. Recently, our Department co-ordinated a 
large, independent, randomised, double-blind multicentre trial to determine the effects 
of pegylated interferon-α treatment in HBeAg-positive patients either alone or in com-
bination with lamivudine.14 The presence of the complete data set and patient samples 
from this trial enabled us to devise this retrospective cohort study of the outcome of 
pegylated interferon-α treatment in HBeAg-positive patients carrying the YMDD-motif 
mutated virus, which is reported here.
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PAtIents And metHods
study design
In this retrospective, comparative, cohort study, data were compiled from the patient 
files and virological records of a large multicentre trial, previously conducted in our 
department in which the efficacy of pegylated interferon alpha-2b, either alone or in 
combination with lamivudine, was compared in a randomised trial of chronic hepatitis 
B patients.14 In addition, patients treated by the same protocol outside this study were 
also included.
Inclusion and exclusion criteria
Eligible patients were HBeAg-positive with resistance to lamivudine as a result of lami-
vudine treatment before the start of interferon therapy. Resistance was confirmed by 
detection of a mutation in the YMDD motif of the RNA-dependent DNA polymerase gene 
of the virus. All patients with lamivudine-resistant virus were included in this analysis, 
regardless of differences in the subsequent interferon therapy (mono- or combination 
therapy). If mutational data were not available on record, retrospective analysis was 
carried out on the corresponding stored serum samples. Where a time point was miss-
ing from the records, results from the nearest date of sampling were taken, within an 
interval of four weeks.
Patients were excluded from the study if they were receiving antiviral treatment at the 
time of enrolment in the original study.
treatment and outcome measures
All patients were treated with pegylated interferon alpha-2b either in monotherapy (100 
µg/week) or in combination with lamivudine (lamivudine 100 mg/day) for more than 20 
weeks and were followed-up for at least a further 16 weeks post-therapy.
During treatment and follow-up, patients attended outpatient clinics every 4 weeks 
for routine examination and laboratory tests. Assessments were made at baseline, Weeks 
16, 32 and 52, and after 26 weeks of follow-up, as appropriate.
Outcome measures were assessed at the end of treatment (Week 52) and at the end 
of follow-up (Week 26). The primary outcome measure was loss of HBeAg from serum. 
Secondary outcomes were return to normal of serum ALT levels, concentrations of HBV 
DNA below 200,000 copies/ml and concentrations of HBV DNA below the level of detec-
tion of the assay (Taqman® assay; 400 copies/ml).
biochemical and virological assessments
Viral load was determined by HBV DNA serum levels and seroconversion by the presence 
of HBeAg or anti-HBe. HBeAg and anti-HBe concentrations were determined using a 
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Microparticle Enzyme Immune Assay (MEIA, Abbott, Chigaco, IL). During treatment with 
interferon, HBV-DNA serum levels were determined by an in-house qPCR, (Taqman® 
assay) calibrated using Eurohep HBV DNA standards.15 Used quantitatively, the Taqman 
assay enables accurate determination to levels of 1,000 copies/ml.16 HBV genotypes and 
mutation analysis of the YMDD motif at the rtM204M side of the viral polymerase gene 
were determined using the Inno-Lipa assay (Innogenetics Ghent, Belgium).
The extent of liver inflammation was determined by measuring serum alanine ami-
notransferase (ALT) levels. To correct for the heterogeneity of local assays, ALT levels 
are expressed as values representing a ratio to local upper limit of normal (x ULN) and 
shown as medians with their range.
statistical analysis
Continuous variables are expressed as median with their range. Median scores were 
compared by Wilcoxon Signed-Rank Test. The Mann-Whitney test was used for the com-
parison of groups. A two-tailed p value of <0.05 was considered statistically significant. 
All analyses used SPSS (version 12.0.1; Chicago, IL, USA).
Subgroup analyses were performed to determine whether known predictors of 
response to therapy accounted for response to pegylated interferon treatment in this 
study. The most frequently cited predictors of response include; previous interferon-
alpha treatment, genotype, high ALT levels and low viral load.13, 14
resuLts
Sixteen HBeAg-positive patients fulfilled the study criteria. The baseline characteristics 
of the patients are shown in Table 1.
Of the patients in this analysis, the majority (12/16) received pegylated interferon al-
pha treatment monotherapy and the remaining four were treated with the same weekly 
dose of pegylated interferon together with 100 mg of lamivudine per day (combination 
therapy). Fifteen of the 16 patients received treatment for 52 weeks and, for 13 patients, 
all data (ALT, HBV-DNA and e-status) were available at 26 weeks of follow-up. In viral 
samples from two patients only faint mutation bands were visible by the Inno-Lipa As-
say.
Hbeag-status
Two of 16 patients (12.5%; 95% ci -6.0% to 31%) seroconverted to HBeAg negative, and 
these two patients also had a sustained virological and biochemical response (HBV-DNA 
levels less than 105 copies/ml and normal ALT at 26 weeks follow up).
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Viral load
The median viral load for the whole patient group decreased by 1.5 10log copies/ml to 
7.9 (range 1.7–10.0) during the treatment period (p=0.001). However, this reduction was 
not sustained and by 26 weeks after treatment cessation the viral load rebounded to a 
median of 8.7 10log copies/ml (range 2.6–10.3) (Table 2).
response assessed by alt measurements
At baseline all patients had elevated ALT levels and a high viral load (Table 1). By Week 
52, ALT levels decreased to a median of 1.3 xULN (range 0.9–11.6), which is significant 
compared with baseline (p=0.047) (Table 2).
After discontinuation of treatment, ALT levels increased to a median of 2.3 xULN 
(range 0.9–5.1) by 26-weeks of follow-up. Only 3 (19%) patients had sustainable normal 
ALT levels.
sustained response
By 26 weeks of follow up only 2 of 16 (12.5%;95% ci -6.0% to 31%) patients could be 
considered as sustained responders to treatment with pegylated interferon alpha by 
our primary outcome measure, and only 2/13 (15.4%) patients had viral load below 105 
copies/ml. Only one responder had a HBV DNA less than 400 copies/ml at the end of 
follow-up. It is of note that the two responders were the patients where only very faint 
total PEG-interferon 
monotherapy
Peg-Interferon 
+ lamivudine 
combination therapy
Male/ female gender (*) 14 / 2 10 / 2 4 / 0
Median age (range) 41.5 (25-72) 41.5 (27-72) 41.5 (25-48)
Race (caucasian / asian)(*) 14 / 2 11 / 1 3 / 1
Previous IFN treatment (yes/
no;*)
7 / 9 5 / 7 2 / 2
Median time start PEG-IFN 
after lamivudine (weeks) 
(range)
42.3 (5.3-176.1) 39.9 (5.3-176.1) 64.6 (31.0-100.6)
Fibrosis according Ishak no.
0 / 1 / 2 / 3 / 4 / 5 / 6 // missing (*)
0 / 3 / 1 / 6 / 0 / 1 / 1 // 4 0 / 2 / 1 / 5 / 0 / 0 / 1 // 3 0 / 1 / 0 / 1 / 0 / 1 / 0 // 1
Median ALT x ULN 3.5 (1.5-11.0) 3.6 (1.5-11.0) 3.5 (1.7-7.2)
Median 10log HBV-DNA 9.4 (8.7-10.4) 9.3 (8.7-10.4) 9.8 (9.1-10.2)
Genotype A/D/other (*) 6 / 6 / 4 5 / 5 / 2 1 / 1 / 2
YMDD mutants V / M+I / M+V 
/ M+V+I (*)
1 / 4 / 6 / 5 1 / 2 / 4 / 5 0 / 2 / 2 / 0
(*) number of patients
table 1. Baseline characteristics for the total group and the subgroups peg-interferon monotherapy and 
peg-interferon + lamivudine combination therapy.
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mutation bands were visible in the initial Inno-Lipa assay. Both responders were 48 
years of age, an Asian male, interferon naive and a Caucasian male who had received 
prior interferon-α therapy. Time elapsed after discontinuation of lamivudine was 64.5 
and 31.0 weeks and fibrosis according Ishak was 5 and 1 respectively. One patient had 
genotype B and the other genotype A. Both harboured the M552M + M552I mutation. 
ALT levels were 7.2 and 4.2 times elevated and HBV DNA levels were 9.1 and 9.7 10log 
copies/ml respectively. None of the baseline characteristics was found to be significantly 
different compared to the nonresponders. One other patient had a normal ALT level 
after 26 weeks of follow up, but no HBe-seroconversion and HBV DNA above 105 copies/
ml.
monotherapy or combination therapy
The majority of the patients 12/16 (75%) were treated with pegylated interferon alpha-
2b monotherapy. The baseline characteristics of these patients did not differ significantly 
from those receiving combination therapy (Table 1).
After 52 weeks of treatment the ALT levels had decreased equally in both groups 
(p=0.791). In the combination therapy group, ALT levels continued to decrease during 
follow up and the median ALT level was normal at end of follow up which was signifi-
cantly lower (p=0.05) (Table 2). For the monotherapy group, despite achieving similar 
ALT levels to the combination group at week 52, at the end of follow up the ALT levels 
increased to 2.5 x ULN (Table 2.)
Although the decrease in viral replication was more marked in the group receiving 
lamivudine in addition to interferon (5.6 10log compared with 1.4 log10 copies/ml) dur-
ing treatment, by 26-weeks after therapy overall viral levels for both groups were not 
significantly different (p=0.643) (Table 2).
baseline Week 52 Week 26 follow-up
ALt HBV dnA ALt HBV dnA ALt HBV dnA
Total n=16
3.5
(1.5-11.0)
9.4
(8.7-10.4)
1.3
(0.9-11.6)1
7.9
(1.7-10.0)1
2.3
(0.9-5.1)1
8.7
(2.6-10.3)1
Monothera-
py n=12
3.4
(1.5-11.0)
9.3
(8.7-10.4)
1.4
(0.9-11.6)
7.9
(4.3-9.5)1
2.5
(1.5-5.1)
8.7
(8.1-10.3)1
Combina-
tion therapy 
n=4
3.5
(1.7-7.2)
9.8
(9.1-10.2)
1.3
(1.1-2.5)
4.2
(1.7-10.0)
1.0
(0.9-3.1)2
6.7
(2.6-10.1)
table 2. The course of liver inflammation as measured as ratio of ALT as upper limit of normal and viral 
load (10log copies/ml) at baseline, end of treatment (week 52) and 26 week of follow-up for the total 
group and the subgroups receiving PEG-interferon-α monotherapy or PEG-interferon-α + lamivudine 
combination therapy. Number in superscript (1) indicate a significant difference (p<0.05) compared to 
the baseline value (1). Number in superscript (2) indicate a significant difference (p=0.05) between two 
groups. No significant differences at any time point were found between mono or combination therapy.
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None of the 12 (0%) patients receiving pegylated interferon alpha-2b monotherapy 
had e-loss, normal ALT level or HBV DNA level below 105 copies/ml at the end of follow-
up. Both responders were in the group that received combination therapy.
dIscussIon
This is the largest study to date on the response to pegylated interferon-α treatment 
of HBeAg-positive hepatitis B patients who have YMDD-mutated virus after previous 
lamivudine treatment. Previous studies with this patient group used non-pegylated 
interferon-α and were limited in the number of patients studied,2-4 the length of treat-
ment (six months) and treatment schedules. The small number of responders to treat-
ment prevented us from drawing definitive conclusions about the benefits of interferon 
therapy in this group. In contrast to the previous studies, in our larger study, all patients 
were treated with pegylated interferon-α for 52 weeks, in accordance with present 
guidelines and recommendations.13, 17
In our group of 16 patients, two (12.5%) responded positively to pegylated interferon-α 
treatment with HBe-seroconversion, a drop in viral load and normalization of ALT levels. 
This response is lower than that observed in other trials of pegylated interferon-α treat-
ment for HBeAg-positive patients, where the percentage of e-loss was over 30%.14, 18 
However, the response rate was in line with that observed in the earlier trials with 
lamivudine-resistant patients, where between 16% and 22% of patients responded to 
pegylated interferon-α.2-5 If we limit the analyis to the patients receiving monotherapy 
PEG-interferon-α none of the twelve (0%) responded to therapy.
There are several proposed predictors of response to treatment with interferon, includ-
ing; previous interferon-α treatment, genotype, high ALT levels and low viral load.13, 14 
In this small study we performed a sub-group analysis to determine which, if any, could 
explain the observed marked lack of response to pegylated interferon-α. None of these 
predictors were found to influence treatment outcome.
We previously found that rate of e-loss was 25% in patients with genotype D virus, 
compared with 47% in those with genotype A. 19 Other studies concur that genotypes 
C and D are less responsive to interferon-α treatment compared with genotypes A and 
B.20-23 A large randomised trial with pegylated interferon alpha-2a found no significant 
difference for response according to genotype, however a trend for higher responses 
in patients with genotype A was observed. 18 In our study of patients carrying YMDD-
mutated virus, the relationship between genotype and treatment response was unclear. 
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Both responders had genotypes that respond more favourably to treatment (genotypes 
A and B).
In our study it was striking that all patients with clear lamivudine resistance were unre-
sponsive to interferon therapy. Notwithstanding the possibility that other unidentified 
factors may have influenced outcome, and although immunomodulatory therapy has 
not previously been linked to therapy failure with nucleoside analogues,24 the findings 
in our study may suggest that YMDD-mutation impairs the immune response to HBV 
and reduces the efficacy of pegylated interferon-α treatment. In support of our putative 
explanation, both responders had, in contrast to the other subjects, very faint bands in 
the Inno-LiPA assay, which has a detection limit of about 5%. This assay was not formally 
quantified but this qualitative assay suggests that these patients had only a low quantity 
of mutant virus.
Our results might suggest that, for subjects with emerging lamivudine resistance, 
early pegylated interferon-α therapy may be beneficial. Alternatively, other nucleoside 
analogues, such as adefovir, tenofovir and entecavir, which have been shown to be 
effective against lamivudine-resistant virus, may present a treatment option for this 
patient group.25-27
Although suggestive of the negative impact of the presence of the YMDD-mutation on 
pegylated interferon-α treatment, this study is too small to yield definitive results. More 
data are needed to further determine the effect of the YMDD-mutation on the efficacy 
of pegylated interferon-α treatment. Whether PEG-interferon-α combination therapy 
with other nucleoside/nucleotide analogues is benificial for patients with lamivudine 
resistance has to be determined. This study is too small to make definite conclusions. 
The timing of the therapy may be of importance as both responders receiving combina-
tion therapy had only little amounts of mutant virus present in a sensitive assay. In our 
opinion, an analysis of the patient subgroup harbouring an YMDD-mutation should be 
included in all future studies of PEG-IFN in chronic hepatitis B.
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ABstrAct
Background: The nucleotide analogues, tenofovir disoproxil fumarate and adefovir dipiv-
oxil, inhibit viral replication and are both effective against the hepatitis B virus.
Methods: In our department, tenofovir was prescribed in addition to lamivudine for the 
treatment of lamivudine resistant chronic hepatitis B. After administration of adefovir, 
10 patients were switched to adefovir monotherapy. We studied changes in HBV DNA 
and ALT in these patients.
Results: The median treatment duration with tenofovir was 78 weeks resulting in a me-
dian viral load reduction of 5.4 (range 6.8 to 2.3) log10 copies/ml compared to baseline 
(p=0.005). Two patients had an increase >1 log10 copies/ml during tenofovir treatment. 
After the switch to adefovir, 6 out of 10 patients had an HBV DNA >4 log10 copies/ml and 
the median HBV DNA increased from 2.8 to 4.5 log10 copies/ml (p=0.017). The factors 
associated with relapse were HBV DNA PCR positivity at the time of switch and genotype 
B or D. ALT levels at the beginning of tenofovir treatment also might be a factor. Retreat-
ment with tenofovir (n=3) resulted in a rapid decline in HBV DNA.
Conclusion: Tenofovir is a potent antiviral drug. Switching to adefovir resulted in viral 
relapse in 60% of patients and retreatment with tenofovir resulted again in viral decline, 
which suggests that tenofovir is a more potent antiviral agent.
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IntroductIon
Although 350-400 million people worldwide are infected with hepatitis B, to this 
date, treatment is frequently unsuccessful. Interferon-α (IFN) treatment or pegylated 
interferon-α (PEG-IFN) results in a sustained response in 30-40% of treated patients. 1, 2 
Many rely on long-term viral suppression with nucleoside or nucleotide analogues 
to prevent disease progression. Nucleosides or nucleotides act by inhibiting the viral 
polymerase, thereby suppressing the viral replication of HBV and improving serum 
transaminase levels and liver histology. In HBeAg-positive patients, the loss of hepatitis 
B antigen (HBeAg) is enhanced. 3-6 The long-term treatment may select for mutations 
within the viral polymerase that promote antiviral resistance resulting in an increase in 
liver inflammation and worsening of liver histology. Lamivudine has a high resistance 
rate of 15-30% after one year of treatment, which increases to 60-70% after continuous 
treatment. 7
The nucleotides, tenofovir disoproxil fumarate and adefovir dipivoxil, exhibit both 
activity against wild-type virus and lamivudine resistant mutants in vitro and in vivo. 8-10 
Tenofovir disopoproxil fumarate is an oral prodrug of tenofovir, a nucleotide (nucleoside 
monophosphate) analogue with activity against retroviruses, including HIV-1, HIV-2 and 
hepadnaviruses. Following absorption, tenofovir DF is rapidly converted to tenofovir, 
which is metabolised intracellularly to the active tenofovir diphosphate. The active form 
of tenofovir is a competitive inhibitor of HBV transcriptase and terminates the growing 
DNA chain. 11-13
Several small studies suggest a more potent antiviral effect of tenofovir compared to 
adefovir. 9 It is not known whether viral suppression is maintained after switching to 
adefovir or whether it is effective in case of viral breakthrough on tenofovir treatment, 
however several cases suggest the loss of efficacy in some patients. 14, 15 In our Depart-
ment, tenofovir was added to lamivudine to combat viral breakthrough due to lamivu-
dine resistance during a period in which adefovir was not yet available. After adefovir, 
dipivoxil became available as a registered product and the tenofovir containing regimen 
was switched to adefovir monotherapy. Its availability enabled us to study the ability of 
adefovir treatment to sustain tenofovir induced disease remission.
PAtIents And metHods
study design
In this retrospective cohort study, data were compiled from patient files and virological 
records from patients treated for chronic hepatitis B virus infection at our Department.
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Eligible patients were treated with tenofovir disoproxil fumarate after the emergence 
of genotypic lamivudine resistance and in whom therapy was switched to adefovir 
monotherapy. All patients were included in this analysis regardless of HBeAg status or 
duration of tenofovir therapy. HBV DNA >104 copies/ml at the start of tenofovir treat-
ment was required.
treatment and outcome measures
All patients were lamivudine resistant and subsequently treated with tenofovir diso-
proxil fumarate either in monotherapy (245 mg/day) or in combination with lamivudine 
(100mg/day) prior to switching to adefovir monotherapy (10 mg/day). There was no 
overlap with tenofovir and adefovir treatment. Tenofovir (245 mg/day) monotherapy 
or combination therapy of tenofovir with lamivudine (100mg/day) was started in some 
subjects with proven failure to adefovir therapy (relapse after the switch). During treat-
ment, patients attended our outpatient clinic on a regular basis for routine examination 
and laboratory testing.
Outcome assessments were made at the initiation of lamivudine, start of tenofovir 
treatment, at weeks 12 and 24 of tenofovir therapy, the end of tenofovir therapy/ start 
of adefovir therapy and last measurement the subject was on adefovir treatment. The 
primary outcome measure was the change in viral load. Secondary outcomes were con-
centrations of HBV-DNA below the limit of detection of the assay (Taqman® assay; 373 
copies/ml), HBV-DNA below 103 copies/ml and serum alanine aminotransferase (ALT) 
levels <1 times the upper limit of normal (ULN).
biochemical and virological assessments
HBV-DNA serum levels were measured with an in-house quantitative PCR (Taqman® 
assay) calibrated using Euroheb HBV-DNA standards. 16 This Taqman assay enables ac-
curate quantitative determination of HBV to levels of 1000 copies/ml and has a lower 
limit of detection of 373 copies/ml. 17 The extent of liver inflammation was determined 
by measuring ALT levels using automated techniques and values are expressed as a ratio 
to the upper limit of normal (xULN).
For sequence analysis, the total HBV genome was sequenced sequentially with primers 
as described before. 18 These sequence products provided information on mutations re-
lated to lamivudine, adefovir and tenofovir resistance. The analysis was performed using 
an ABI3100 instrument (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) 
and analysed using BioEdit Software (v7.05), (Ibis Therapeutics, Carlsbad, CA, USA).
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statistical analysis
Continuous variables are expressed as medians with their range. Dependent variables 
were compared using the Wilcoxon’s Signed Ranks-test and independent variable by 
Mann-Whitney U test, Chi-square or Fisher exact test as appropriate.
A two tailed p-value of <0.05 was considered statistically significant. For all analyses, 
SPSS (version 14.0.0; Chicago, IL, USA) was used.
resuLts
Ten patients fulfilled the study criteria. The baseline characteristics are shown in Table 
1. Median treatment duration with tenofovir until the switch to adefovir was 78 weeks 
and resulted in a rapid and significant decline of 5.4 (6.8 to 2.3) log10 copies/ml in viral 
load (p=0.005) compared to baseline (Fig. 1 and 2). Maximum HBV DNA decline during 
tenofovir therapy was 6.1 (7.4 to 2.4) log10 copies/ml, but HBV DNA increased slightly and 
at the end of tenofovir therapy median serum HBV DNA was 2.8 log10 copies/ml, with 
40% (4/10) patients being PCR negative. At the end of tenofovir treatment 30% (3/10) 
patients had a viral load above 103 copies/ml. Two of those patients (patients 2 and 9) 
clearly showed phenotypic resistance to tenofovir as both had over 1 log10 increase of 
HBV-DNA, the other patient (patient 7) had an increase in HBV DNA from PCR negativity 
to 3.2 log10 copies/ml just before the switch to adefovir. No genotypic resistance associ-
ated with tenofovir could be documented. None of the patients experienced a hepatic 
flare. ALT levels declined significantly from 2.4 xULN at start of therapy to 0.74 xULN 
(p=0.013) at the end of tenofovir therapy, resulting in ALT levels <1 ULN in 80% (8/10) of 
the patients and all had ALT level <1.5 times the ULN.
Switching tenofovir to adefovir had a negative effect in 60% (6/10) of patients. The 
viral load for the total group increased significantly to 4.5 log10 copies/ml during ad-
efovir therapy (p=0.046). In the relapse group, the increase in HBV DNA was 2.2 log10 
copies/ml and all patients had a viral load of >104 copies/ml. The increase in HBV DNA 
was not accompanied by an hepatic flare as ALT levels remained 0.74 times the upper 
limit of normal and only one patient in the relapse group had an ALT level >2 times 
ULN. Resistance testing revealed only the rtL80I and rtM204I mutation in the patient 
responding poorly to tenofovir (patient 9). Genotype related polymorphisms were not 
detected, especially not those published in the literature. 19
To study the factors influencing relapse the group of non-relapsers was compared to the 
relapsers. Patient characteristics were comparable for both groups, as was the duration 
of lamivudine and tenofovir treatment (Table 1). HBV DNA levels did not differ between 
the two groups during lamivudine therapy, up to 24 weeks of treatment with tenofovir. 
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Baseline factors Total group (n=10) Non-relapsers (n=4) Relapsers (n=6) P-value
Age (years) 33 (18-45) 33 (18-42) 36 (26-45) 0.831
Race (Caucasian / Asian / 
Other) (%)
40/40/20 25 /50 / 25 50 / 33 / 17 0.732
Sex- male (%) 70 100 50 0.200
HBeAg positive (%) 80 75 83 1.0
Cirrhosis (%) 20 0 33 0.467
Previous IFN (%) 50 25 68 0.524
Genotype (A / B / C / D (%) 20/40/10/30 50/25/25/0 0/50/0/50
Geno B+D vs rest (% geno 
B+D)
70 25 100 0.033
HBV DNA start TEN 8.45 (4.62-9.66) 8.10 (4.62-8.84) 8.61 (7.96-9.66) 0.240
ALT start TEN (xULN) 2.43 (0.36-18.50) 5.74 (3.33-18.50) 1.29 (0.36-11.83) 0.055
Duration of LAM prior to TEN 
(weeks)
92.14 (52.14-160.0) 78.43 (64.0-105.43) 127.5 (52.14-160) 0.286
LAM resistant before initiation 
TEN (weeks)
47.43 (5.0-120.86) 47.43 (23-0-62.0) 54.90 (5.0-120.86) 0.831
Factors associated with 
relapse
Duration TEN therapy (weeks) 77.57 (51.0-105.86) 83.5 (77.14-94.0) 62.57 (51.0-105.86) 0.831
Duration TEN + LAM 
combination therapy (weeks)
53.57 (2.86-92.0) 71.57 (14.0-89.0) 48.50 (2.86-92.0) 0.336
HBV DNA start LAM 8.93 (7.28-10.20) 9.04 (7.28-9.11) 8.64 (7.33-10.20) 0.796
ALT start LAM 12.03 (0.64-23.75) 12.18 (12.03-13.13) 1.01 (0.64-23.75) 0.439
Lowest HBV DNA during LAM# 3.88 (2.84-7.73) 3.33 (2.84-4.59) 3.96 (2.84-7.73) 0.224
Lowest HBV DNA during TEN 2.27 (2.27-4.42) 2.27 (2.27) 2.27 (2.27-4.42) 0.517
Time HBV DNA <103 stop TEN 
(weeks)
25.0 (8.86-62.86) 22.5 (8.86-62.86) 25.0 (11.71-47.0) 0.317
HBV DNA stop TEN 2.84 (2.27-6.43) 2.27 (2.27) 3.01 (2.84-6.43) 0.007
HBV DNA neg stop TEN (%) 40 100 0 0.05
HBV DNA <103 stop TEN (%) 70 100 50 0.200
ALT stop TEN 0.74 (0.53-1.30) 0.83 (0.53-1.30) 0.70 (0.58-1.08) 0.522
HBeAg positive at switch (%) 70 50 83 0.500
table 1. Baseline characteristics for the three different groups ( total group, non-relapsers, relapsers). 
P-values are outcome of comparison between non-relapsers and relapsers. Factors associated with 
relapse at baseline (start of tenofovir therapy) and before, during and after tenofovir treatment. LAM = 
lamivudine, TEN = tenofovir, HBV DNA neg = undetectable by PCR (lower limit of detection 373 copies/
ml), HBV DNA in copies/ml, # = median viral load of the lowest HBV DNA level reached during tenofovir at 
any time point for each individual.
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However at the end of tenofovir treatment the viral load was significantly higher in the 
relapse group (3.0 vs. 2.3 log10 copies/ml, p=0.007) and 0% vs. 100% had undetectable 
HBV DNA (p=0.05). After the switch the viral load remained low for the non-relapsers 
and increased in the relapse group with 2.2 log10 copies/ml to 5.4 log10 copies/ml at 
the end of follow-up. Despite ALT levels at start of lamivudine treatment and HBV DNA 
at start of lamivudine and tenofovir treatment were comparable, ALT levels at start of 
tenofovir therapy were higher in non-relapsers (5.7 vs. 1.3 times ULN) and showed a 
 
HBV DNA       
Total Group 8.93 (7.28-10.20) 8.45 (4.62-9.66) 4.32 (2.84-6.59) 2.84 (2.27-4.82) 2.84 (2.27-6.43) 4.50 (2.27-8.58) 
Non-relapsers 9.04 (7.28-9.11) 8.10 (4.62-8.84) 3.16 (2.84-4.39) 2.65 (2.27-3.73) 2.27 (2.27) 2.56 (2.27-2.84) 
relapsers 8.64 (7.33-10.20) 8.61 (7.96-9.66) 5.03 (2.84-6.59) 2.84 (2.27-4.82) 3.01 (2.84-6.43) 5.39 (4.21-8.58) 
p-value 0.796 0.240 0.176 0.659 0.007 0.01 
ALT (xULN)       
Total Group 12.03 (0.64-23.75) 2.43 (0.36-18.50) 1.30 (0.83-2.65) 0.86 (0.58-1.60) 0.74 (0.53-1.30) 0.74 (0.40-2.92) 
Non-relapsers 12.18 (12.03-13.13) 5.74 (3.33-18.50) 2.38 (0.83-2.65) 0.97 (0.60-1.05) 0.83 (0.53-1.30) 0.74 (0.40-0.95) 
relapsers 1.01 (0.64-23.75) 1.29 (0.36-11.83) 1.10 (1.10-1.30) 0.81 (0.58-1.60) 0.70 (0.58-1.08) 0.73 (0.44-2.92) 
p-value 0.439 0.055 0.285 0.521 0.522 0.670 
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8.58)
n-
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9.04 (7.28-
9.11)
8.10 (4.62-
8.84)
3.16 (2.84-4.39) 2.65 (2.27-3.73) 2.27 (2.27) 2.56 (2.27-
2.84)
relapsers 8.64 (7.33-
10.20)
8.61 (7.96-
9.66)
5.03 (2.84-6.59) 2.84 (2.27-4.82) 3.01 (2.84-6.43) 5.39 (4.21-
8.58)
p-value 0.796 0.240 0.176 0.659 0.007 0.01
ALt 
(xuLn)
Total 
Group
12.03 (0.64-
23.75)
2.43 (0.36-
18.50)
1.30 (0.83-2.65) 0.86 (0.58-1.60) 0.74 (0.53-1.30) 0.74 (0.40-
2.92)
Non-
relapsers
12.18 (12.03-
13.13)
5.74 (3.33-
18.50)
2.38 (0.83-2.65) 0.97 (0.60-1.05) 0.83 (0.53-1.30) 0.74 (0.40-
0.95)
relapsers 1.01 (0.64-
23.75)
1.29 (0.36-
11.83)
1.10 (1.10-1.30) 0.81 (0.58-1.60) 0.70 (0.58-1.08) 0.73 (0.44-
2.92)
p-value 0.439 0.055 0.285 0.521 0.522 0.670
Figure 2. Course of HBV DNA during treatment for the total group, non-relapsers and relapsers at several 
time points during lamivudine, tenofovir and adefovir therapy. The median HBV DNA (log10 copies/ml) and 
ALT levels as a ratio to the upper limit of normal (xULN) and their range at these time points are provided 
in the table. P-values are provided for the comparison between non-relapsers and relapsers.
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trend to significance (p=0.055). ALT levels normalised in both groups, but ALT decline 
was higher for non-relapsers (5.1 vs. 0.5 times ULN ALT, p=0.055). HBeAg loss occurred 
more often in non-relapsers. One patient in the relapse group had HBeAg reversion. 
After the switch HBeAg status differed between the two groups (25% vs. 100% HBeAg 
positivity, p=0.033). Genotype B or D were significantly more common in patients with 
relapse during adefovir treatment ( p=0.033).
salvage therapy
In three patients tenofovir was restarted resulting in a rapid decline of HBV DNA lev-
els. Two subjects treated (patients 3 and 7) with tenofovir + lamivudine combination 
therapy reached a viral load below 103 copies/ml within 12 weeks. The other subject 
(patient 2) had a 3.5 log10 copies/ml decline after 18 weeks of treatment with tenofovir 
mono therapy. In the patient (patient 9) with poor response to tenofovir treatment and 
no decline in viral load addition of lamivudine resulted in a 1.3 log10 copies/ml decline 
in viral load, but HBV DNA levels rebounded to the same level as before the addition of 
lamivudine.
dIscussIon
The majority of patients infected with hepatitis B, irrespective of HIV infection, showed 
a good response to tenofovir, with an overall decrease in viral load of at least 4 log10 
copies/ml. 9, 20-23 Breakthrough during tenofovir therapy has not been reported in HBV 
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Figure 1. Course of HBV DNA during Tenofovir treatment and after the switch to adefovir therapy in 10 
patients. The dashed vertical line indicates the time of the switch to adefovir.
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mono-infected patients. Although others have not confirmed a reduction in sensitivity, 
a mutation (rtA194T) that results in a reduction in in-vitro sensitivity to tenofovir has 
been reported. 11, 24 Its frequency and clinical impact remains to be seen. Recently, the 
variants rtV214 and rtQ215S in combination with lamivudine associated results have 
been reported to be associated with a reduced sensitivity to tenofovir.
We studied 10 patients infected with lamivudine resistant chronic HBV treated with 
tenofovir. The median decline during treatment was 5.4 log10 copies/m. HBV DNA was 
<103 copies/ml in 70% and PCR–negativity was reached in 40% of patients. Two patients 
experienced increases in viral load of over 1 log and increases in PCR negativity to over 
103 copies/ml was observed in an additional patient. Resistance analysis did not reveal 
mutations within the polymerase gene except lamivudine associated mutations in one 
patient.
Six of ten patients in this study failed on adefovir therapy. Three patient already had 
suboptimal viral suppression (HBV DNA >103 copies/ml), but the other 3 patients had 
low viral loads. No viral variants were detected, except the lamivudine associated mu-
tations, rtL80I + M204I, in one subject. The known mutations associated with adefovir 
resistance (rtV84M, rtA181V/T, rtQ214A, rtQ215S, rtN236D/T) were ruled out by geno-
typic testing. Therefore, resistance to adefovir does not seem to play a role in the relapse 
after switching therapy. These findings are in concordance with the patients described 
before in which viral relapse was observed after switching tenofovir to adefovir. 14, 15 A 
polymorphic form of the HBV genotype A2 rtL217R is sensitive to tenofovir but associ-
ated with non-response to adefovir has been described. A similar polymorphic form was 
described for the genotype D3 rtI233V, which was sensitive to tenofovir or entecavir 
but displayed a 6-10 fold decreased susceptibility to adefovir. 19, 25 In our population, no 
genotype specific polymorphisms were found. However, genotypic influences have not 
been ruled out, as there was an association between genotype B or D and relapse. How-
ever, in large randomised studies of patients treated with adefovir or entecavir, HBV DNA 
suppression was comparable across HBV genotypes A-D. 26, 27 Genotypes might influence 
treatment outcomes. Some studies reported different rates for genotypes in patients 
treated with lamivudine. 28-30 In adefovir treated patients, resistance was associated with 
HBV genotype D infection. 31 Further studies involving a larger number of patients with 
various genotypes are required to explore the possible association between genotype 
and relapse or the development of resistance.
If relapse cannot be explained by the development of resistance, there must be varying 
pharmacodynamic and pharmacokinetic properties in the host and different responses 
(viral dynamics and viral kinetics) to antiviral therapy. In vitro data suggest that adefovir 
and tenofovir are equipotent molecularly. 8, 32 The 10 mg dose for adefovir was chosen 
for safety reasons (i.e. nephrotoxicity) and the higher dose of 30 mg proved to be more 
Viral relapse switching tenofovir to adefovir 57
potent in a head to head comparison indicating that the 10 mg dose is marginal for HBV 
DNA suppression. 5 Thus, a 245 mg dose of tenofovir is likely to be more effective.
A head to head comparison showed a significantly greater reduction in HBV DNA and 
higher rates of PCR negativity in patients receiving tenofovir, illustrating viral dynamics 
are in favour of tenofovir. 9 The dose of tenofovir could have been sufficient for potent 
viral suppression by tenofovir and the relapse of HBV DNA after the switch could have 
been the result of adefovir under dosing. In the group of relapsers, the viral load, at the 
time of switch, was significantly higher suggesting suboptimal viral suppression. The 
difference in potency is further underlined by the potent inhibition of viral replication 
with the reintroduction of tenofovir. Two patients reached a viral load below 103 copies 
within 12 weeks and the third patient had a 3.5 log10 decline in viral load over a period 
of 18 weeks, which is similar in magnitude to the other two patients. In one patient, 
lamivudine was added to adefovir resulting in a 1.3 log10 decline in HBV DNA, but the 
viral load quickly rebounded.
In conclusion, our data demonstrate that tenofovir is a potent inhibitor of viral replica-
tion, but efficacy is partially lost in some patients with prolonged treatment. Switching 
tenofovir to adefovir monotherapy results in a relapse of viral load in 60% of patients. 
Specifically, factors such as viral load at the time of switch and genotype B or D were 
associated with an increased risk of relapse. ALT levels at the initiation of tenofovir treat-
ment could also be a factor influencing treatment outcome. Relapse did not seem to be 
a result of treatment-resistance and the reintroduction of tenofovir resulted in a strong 
and rapid decline in viral load. Patients on tenofovir therapy should not be switched to 
adefovir monotherapy.
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ABstrAct
Entecavir has potent activity against hepatitis B virus. Drug resistance has not been 
reported in nucleoside naïve patients and is low in lamivudine-refractory patients.
A 43 year-old man was treated with lamivudine for HBeAg-positive chronic hepatitis 
B. A viral breakthrough due to a drug resistant mutant was observed and entecavir 1 
mg daily was added. After the viral load had been near the lower detection range of the 
PCR assay for 30 weeks, lamivudine was discontinued. The serum HBV DNA remained 
low until a second viral breakthrough was observed after 45 weeks of entecavir mono-
therapy. Entecavir was switched to tenofovir disoproxil 245 mg daily, which resulted in a 
decline below 1000 copies/ml. Sequence analysis revealed the presence of rtL180M and 
rtM204V lamivudine resistant associated mutations at the start of entecavir treatment. 
During entecavir treatment, the rtS202G mutation was selected. Retrospective analysis 
revealed that during lamivudine treatment three other mutations had been selected as 
well, namely rtE1D, rtV207L and rtI220L.
Conclusions: We describe the first case of entecavir resistance in a lamivudine resistant 
patient with good initial suppression of viral replication for 70 weeks. Based on the data 
from cross-resistance and sensitivity testing in vitro and treatment outcomes, tenofovir 
proves to be a good treatment option for entecavir-resistant patients.
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IntroductIon
Hepatitis B infection remains a global health problem despite the availability of effective 
vaccines. It is estimated that 350-400 million people worldwide are chronically infected. 
If left untreated, about a third will develop progressive and possibly fatal liver disease. 1 
Drugs inhibiting viral replication have a higher on-treatment response compared to 
interferon-alpha or PEG-interferon-alpha, but relapse is frequent after treatment dis-
continuation. Treatment with the first registered small-molecule inhibitor of the viral 
polymerase, lamivudine, results in a rapid 4-5-log decline in viral load and has been 
shown to improve liver histology after one year of treatment. In addition a reduction of 
the incidence of hepatic decompensation and hepatocellular carcinoma compared to 
placebo treatment in patients with cirrhosis was observed. 2-4 A major drawback is the 
emergence of mutations within the viral polymerase gene rendering resistance result-
ing in a resistance rate of approximately 20% per year. 5 Adefovir dipivoxil on the other 
hand has a slower rate of resistance development relative to lamivudine and both drugs 
have different resistance patterns. 6, 7
A new promising drug, a carboxylic 2’-deoxyguanosine analogue entecavir, is rapidly 
metabolized to its active triphosphate metabolite. 8 This drug has recently been regis-
tered and a dose of 0.5 mg results in an approximately 7-log decline in HBeAg-positive 
and 5-log decline in HBeAg-negative, nucleoside naive patients. Entecavir (1 mg QD) is 
also effective against lamivudine resistant strains, however the reduction in viral load 
is less compared to wildtype. 9-11 The resistance rates in entecavir are very favorable. In 
large phase III studies, only 18 HBV DNA rebounds in over 900 person years of treatment 
were observed in nucleoside naïve patients treated with entecavir for up to two years of 
treatment. Analysis of these patients revealed no genotypic and phenotypic resistance 
to entecavir. 12 A phase III study for lamivudine refractory patients, revealed 5 out of 141 
patients with viral rebound, two of them with entecavir resistance associated substitu-
tions in the polymerase gene, treated with entecavir for 1 year. In the second year of 
entecavir treatment 17 HBV rebounds were observed in 119 treated patients and in 11 
of them entecavir resistance was detected. 13
Tenofovir disoproxil fumarate is another promising drug and is an acyclic nucleotide 
analogue analogue reverse transcriptase inhibitor, with showed potent activity both in 
in vitro and in vivo studies in wild type and lamivudine resistant HBV in HIV-HBV co-
infected and HBV mono infected patients. 14-16
In this report we describe a case of entecavir resistance after initial successful and pro-
longed viral suppression during entecavir treatment in a lamivudine-refractory patient.
Based on available resistance and drug susceptibility data and the results of our treat-
ment, we discuss the management strategy in case of entecavir-resistance.
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A 43-year old male (weight 87 kg, length 175 cm, BMI 28.4) with chronic active HBeAg 
positive (HBeAg and anti-HBe concentrations were determined using a Microparticle 
Enzyme Immune Assay, MEIA, Abbott, Chigaco, IL) hepatitis B and liver cirrhosis was 
treated in 1994 with IFN-α 5 MU thrice weekly for 30 weeks, but relapsed (fig.1). Lamivu-
dine 100 mg once a day was initiated and serum HBV DNA decreased to undetectable 
levels as detected by an in-house qPCR, calibrated using Eurohep HBV DNA standards. 17 
Used quantitatively, the Taqman assay enables accurate determination to levels of 1,000 
copies/ml and a lower detection limit of 373 copies per ml. 18 This was, accompanied 
by subsidence of liver inflammation (measured by serum alanine aminotransferase 
levels (ALT)). After discontinuation HBV-DNA levels rebounded, accompanied by a post-
treatment flare. Reintroduction of lamivudine 100 mg once daily resulted again in a fast 
decline in HBV-DNA levels below the detection limit and reduction in liver inflammation. 
HBeAg remained positive during treatment. After 230 weeks of continuous lamivudine 
treatment, a hepatic flare was documented as a result of viral breakthrough. The viral 
load rebounded to over 108 copies/ml. Twenty weeks later entecavir 1 mg was added to 
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Figure 1. Viral load dynamics and course of ALT during treatment. Samples negative by PCR were 
calculated as 1.87 x102, half of the range from 0 to the lower level of undetectability of 373 copies/
ml. Samples <1000 copies/ml but positive by PCR were noted as 6.87 x102, which is the value between 
373 and 1000 copies/ml. The upper limit of normal for ALT is 40 U/l. The time points, at which sequence 
analysis was performed, are indicated by arrows and accompanied by the mutations found. Changes in 
the mutation pattern are indicated in bold, underlined or italic.
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the lamivudine regimen, which resulted in a suboptimal decline in viral load of 2.35 log10 
copies/ml. Viral load continued to decline to levels below 104 copies/ml and ALT levels 
around the ULN (40 U/l) after 48 weeks of treatment. However, it took over a year (69 
weeks) of combination therapy to reduce viral levels below 103 copies/ml. The viral load 
was near the lower detection limit by PCR at the long term and HBeAg loss occurred. 
After 96 weeks of combination therapy, lamivudine was discontinued with no effect on 
viral load or extent of liver inflammation. At week 144 of entecavir treatment, after the 
HBV DNA had been below 103 copies/ml for over 70 weeks, a viral load of 5.69 x104 cop-
ies/ml was documented and HBeAg became positive again. Gradually the viral replica-
tion increased to 1.27 x106 copies/ml and remained at this level. The ALT levels remained 
low. Entecavir 1mg once daily was switched, without overlap, to tenofovir disoproxil 
(Viread) 245 mg once daily. After 25 days of treatment, the viral load was again below 103 
copies/ml and the patient underwent HBeAg seroconversion after 6 weeks of therapy. A 
small increase to just above 103 copies/ml was observed. After 63 days of treatment, the 
viral levels were again below 103 copies/ml and remained just above the lower limit of 
detection, but below 103 copies/ml, for over 106 weeks. ALT levels were slightly elevated 
to a maximum of 1.7 times the upper limit of normal and somewhat variable. This might 
be a consequence of his steatosis hepatis.
sequence AnALysIs
For sequence analysis, the total HBV genome was sequenced sequentially with primers 
as described before. 19 These sequence products gave information on mutations related 
to lamivudine and entecavir resistance. The analysis was performed using an ABI3100 
instrument (Applied Biosystems, Niewerkerk a/d IJssel, The Netherlands) and analysed 
using BioEdit Software (v7.05), Ibis Therapeutics, Carlsbad, CA, USA).
The genome was sequenced at different time points during antiviral therapy (see fig. 
1). The sequence of the viral polymerase at the beginning of lamivudine treatment was 
wild type. At the time of lamivudine resistance, the lamivudine-resistance associated 
mutations rtL180M and rtM204I were present. During entecavir treatment, the rtL180M 
mutation remained
present and the rtM204I mutation changed to the rtM204V mutation. The sequence 
of the viral polymerase at the time of breakthrough during entecavir therapy revealed 
the novel rtS202G variant. In addition, three other variants in the reverse transcriptase 
domain were detected at the time of lamivudine resistance. These rtE1D, rtV207L and 
rtI220L variants remained present during entecavir therapy as they were also detected 
in the sequenced samples after breakthrough during entecavir therapy.
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In this report, we describe the results of sequential monotherapy with lamivudine, 
entecavir and tenofovir in a chronic HBV infected patient. In this patient, selection of 
the rtS202G mutation on a background of lamivudine resistance induced entecavir 
resistance although HBV-DNA initial viral suppression was excellent. This patient differs 
from previous reports on entecavir resistance by the prolonged period of vigorous viral 
suppression nearly to the lowest level of detection of the PCR assay before clinical resis-
tance emerged, after an initial slow decline in viral load. In general, persistent replication 
is a major determinant for the emergence of genomic mutations. 7, 20
Entecavir is a 100-300 fold more potent inhibitor of the wild type viral polymerase 
compared to lamivudine. Cell culture data demonstrated entacavir still exhibits potent 
inhibitory capacities of the lamivudine resistant polymerase, although sensitivity is 
decreased 20-150 fold. 21, 22 In the clinical setting, entecavir 1 mg QD proved effective in 
the treatment of lamivudine resistant patients. 9, 11 In the presence of the rtL180M and 
rtM204V mutations and entecavir-associated mutations, the susceptibility to entecavir 
decreased dramatically as seen by an increase in IC50 values by 280 to over 1500 fold. 
23
Sequencing of the viral polymerase in our patient showed the lamivudine-associated 
mutations, rtL180M and rtM204V. In addition, the rtS202G mutation was found. This 
mutation has recently been described in a patient with similar previous treatments 
including lamivudine therapy leading to both rtL180M and rtM204V mutations. This 
patient only had a modest decline of log10 2 copies/ml with a nadir value of 10
5 copies/
ml. 24 The error rate of the HBV reverse transcriptase has been estimated to occur at a rate 
of 10-4 base per replication cycle. 25 Because of the high viral load the emergence of the 
rtS202G mutation conferring resistance to entecavir was a matter of time. 24
Persistent viral replication is a major factor for the development of resistance. Our 
patient, however, had excellent viral suppression for over a year, but the decline in viral 
load was slow and variants could have appeared in the background. Other factors for 
treatment failure such as poor adherence or an inadequate metabolism (absorption, 
bioavailability, metabolism of the prodrug to its active metabolites or phosphorylation) 
does not seem to play an important role in this case. He was adherent as the drug count 
was satisfying. The decline of viral load was excellent on the long term, for which an 
adequate metabolism is obligatory.
Lamivudine treatment was continued for 96 weeks after the start of entecavir. The 
presence of lamivudine in the regimen could put a continuous selection pressure on 
the lamivudine resistant mutants, preventing reversion to wild-type virus. The rtS202G 
mutant could already have emerged during lamivudine. It can take quite a while for a 
drug resistant mutant to become the dominant species and lead to a rise in HBV DNA 
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as kinetics of emerging drug resistant mutants is usually slow. Free replication space is 
necessary for the spread of mutant virus and its availability is linked to the time required 
to observe the mutant (i.e. the increase of viral load). 26 Intrinsic resistance of the mutant 
and its replicative fitness also influences the time to the clinical emergence. These factors 
may in part explain the difference in resistance rates between entecavir and lamivudine. 
Replication fitness of entecavir resistant mutants is diminished to about half compared 
to the wild type virus. The combination of rtL180M + rt202G + rtM204V harbored by our 
patient results in a replicative fitness of about 50% of the wild type virus. 23, 24 Additional 
mutations rtV173L and rtP177S are able to restore replicative fitness to similar levels 
of the wild type. These factors may, in part, explain the difference in resistance rates 
between entecavir and lamivudine as more genetic changes are necessary for a mutant 
to become the dominant strain.
The role of the rtE1D, rtV207L and rtI220L mutations, found during lamivudine therapy 
is not clear. Their impact on sensitivity and replication fitness is unknown, nevertheless 
they remained present during entecavir therapy, which may imply a certain influence of 
these mutations. Patients with lamivudine resistance treated with adefovir frequently 
loose the lamivudine-associated mutations suggesting the mutations rtE1D, rtV207L 
and rtI220L confers an advantage for the virus. 27 Future in vitro research has to clarify 
their impact on drug sensitivity and replication fitness.
Almost no data about the clinical management of entecavir resistance are available. In 
vitro cross-resistance testing gives some insight into the probable outcomes of different 
treatments. All L-nucleoside analogues lamivudine, emricitabine (FTC), telbuvidine (L-
dT), L-dC , L-dA, torcitabine and clemuvidine (L-FMAU) show >100 fold cross resistance 
to different patterns of lamivudine resistance and are therefore not a treatment op-
tion. 14, 22, 28-32 Lamivudine resistant mutants remain susceptible to acyclic phosphonate 
nucleotides like adefovir, tenofovir and alamifovir. 14, 28, 33-35 Adefovir and tenofovir also 
proved to be clinically effective against lamivudine resistant species. 16, 36, 37 Although 
adefovir and tenofovir remain active against lamivudine resistant mutants, their activ-
ity is less. For adefovir, increase of 2.8-16 fold in IC50 values have been reported, while 
tenofovir exhibited only a maximum 3.3 fold increase in IC50 values. 
14, 22, 33, 35 It appears 
lamivudine mutations have an impact on the treatment efficacy of adefovir in the clini-
cal setting. 6, 38 Mutations at the rtL80 site that occur during lamivudine therapy, might 
negatively influence the effectiveness of adefovir. 39, 40 Furthermore, earlier and higher 
rates of emergence of rtA181V/T and rtN236T mutations associated with adefovir resis-
tance have been reported in lamivudine resistant patients during adefovir therapy. 38, 41 
The mutation at codon rt181 mutation has also been found in patients refractory to 
lamivudine. Selection of a mutation at codon rtA181 has been detected during ente-
cavir therapy. 24 As A was substituted to G, its impact on the susceptibility to adefovir is 
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unknown. However molecular modeling showed that the rtA181V/T mutations alter the 
position of codon rtM204 resulting in indirect steric hindrance. 42 Therefore, the rtA181G 
mutation could also effect this site and susceptibility to antivirals, which appears to be 
the case considering the addition of this mutation to the rtL180M + rt202G + rtM204 
mutations reduces IC50 values and replication fitness. 
24 Due to the many possible inter-
actions of lamivudine and entecavir associated mutations with adefovir, this compound 
might not be the most logical choice.
Tenofovir disoproxil (tenofovir) has potent antiviral activity against both the wild type 
and mutant hepatitis B virus. Recently, the mutation rtA194T has been described leading 
to over 10-fold decreased sensitivity, although clinically this did not lead to resistance. 43 
This mutation has no cross-resistance to any other antiviral used for the treatment of 
hepatitis B.
We switched our patient to tenofovir 245 mg once daily, resulting in a rapid decline 
of viral load to below 1000 copies/ml and almost to undetectable levels. In addition, 
HBeAg seroconversion was documented after 1.5 months of treatment. Based on our 
findings and available resistance data on hepatitis B, tenofovir seems to be a good treat-
ment option for entecavir-resistant patients. Longer treatment duration is necessary to 
determine the durability of the viral and biochemical response.
In summary, entecavir resistance also arises in lamivudine-refractory patients with 
prolonged suppression of viral replication. Based on theoretical assumptions and our 
findings, tenofovir seems to be a good treatment option for entecavir-resistant hepatitis 
B.
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ABstrAct
Introduction: Patients with chronic hepatitis B (CHB) who will and who will not respond 
to adefovir (ADV) monotherapy need to be identified in an early stage in order to adjust 
treatment and prevent future development of antiviral resistance.
Methods: In a single center cohort study we investigated seventy-six CHB patients (50% 
HBeAg-positive) treated with long-term ADV monotherapy.
Results: During a median follow-up of 122 (24-185) weeks 42 (55%) patients achieved 
virologic response (VR), defined as HBV DNA levels < 103 copies/mL, and ten patients 
(13%) developed genotypic ADV resistance. Independent baseline predictors of VR were 
HBeAg negativity (HR (hazard ratio) HR 2.98; 95%CI 1.24-7.19; p = 0.02), high ALT levels 
(HR 1.11; 95% CI 1.05-1.18; p = 0.001), and low HBV DNA levels (HR 0.56; 95% CI 0.41-0.75; 
p < 0.001). HBV DNA at week 24 demonstrated a higher predictive value for VR than HBV 
DNA at week 48. Important predictors of genotypic resistance were presence of cirrhosis 
(HR 6.54; 95% CI 1.39-30.9; p = 0.018), and not achieving VR during treatment (HR 6.60; 
95% CI 1.35-32.4; p = 0.008). Patients without VR at week 24 already demonstrated a 
trend towards the emergence of ADV resistance (p = 0.07)
Conclusion: HBV DNA at week 24 was a better on-treatment predictor of VR than HBV 
DNA at week 48, and ADV-resistant mutations developed more frequently in patients 
without VR at week 24. Therefore, our study suggests that virologic response to ADV 
therapy can already be assessed at 24 weeks, instead of the generally recommended 48 
weeks.
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IntroductIon
Chronic hepatitis B virus (HBV) infection is still a serious global health problem with an 
estimated 350 million people chronically infected, and 0.5-1.2 million deaths a year. 1, 2 
With the currently approved treatment options the major goal of treatment is HBV DNA 
suppression in order to prevent development of liver cirrhosis, end-stage liver disease, 
and hepatocellular carcinoma.
Adefovir dipivoxil (ADV) is an oral prodrug of adefovir, a phosphonate acyclic 
nucleotide analogue of adenosine monophosphate. 3 Previous studies demonstrated 
its efficacy in patients with HBeAg-positive and HBeAg-negative chronic HBV infec-
tion, showing significant virologic, biochemical, and histological improvement after 
48 weeks of treatment. 4, 5 However, genotypic resistance rates are up to 29% after five 
years of treatment with ADV. 6 Two mutations (rtN236T, rtA181V) have been described to 
confer resistance to ADV. 7, 8 Other mutations have also been reported to be associated 
with reduced susceptibility to ADV, including the rtA181T and rtI233V mutations, but 
the significance of these mutations remains unclear. 9-13 Furthermore, it is known that 
a significant proportion of patients have slower and poor primary responses to ADV, 
probably related to the suboptimal approved dose. In one study, 25% of patients had a 
less than 2.2 log10 reduction in HBV DNA levels after 48 weeks of treatment. 
14
It is currently recommended that in HBeAg-positive patients treatment can be stopped 
after HBeAg-seroconversion with at least six months of consolidation treatment. In 
HBeAg-negative patients discontinuation may only be possible after HBsAg clearance, 
necessitating long-term therapy for a significant proportion of patients. 15-17 However, 
development of antiviral drug resistance is a major limitation to long-term efficacy of 
nucleos(t)ide analogues and will thus be an important factor in treatment failures. 18 It 
is known that resistance only emerges when replication occurs in the presence of drug 
selection pressure, and complete suppression of viral replication allows little opportu-
nity for resistance to develop. 19 Several studies have already shown that a rapid virologic 
response is associated with lower rates of antiviral drug resistance in HBV patients in 
the long term. 20-22 Therefore, antiviral therapy, once initiated, should aim to suppress 
viral replication as quickly and completely as possible, and patients who will or will not 
respond to ADV monotherapy need to be identified in an early stage in order to adjust 
treatment and prevent future development of antiviral drug resistance.
The primary aim of our observational study was to assess virologic response to ADV 
in patients with chronic hepatitis B virus infection, and to identify baseline and on-
treatment factors associated with virologic response in the setting of clinical practice. 
Secondary aims were to evaluate rates of HBeAg loss, and genotypic resistance rates, 
and to explore associated baseline and on-treatment parameters.
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metHods And mAterIALs
study population
In this retrospective cohort study, all adult HBV patients with compensated liver disease 
and a viral load of at least 4 log10 copies/ mL referred to the Erasmus Medical Center 
Rotterdam from August 2003 to March 2006, who had received ADV monotherapy for 
at least six months, were included in the analysis. Patients were excluded if they had 
decompensated liver disease or a diagnosis of hepatocellular carcinoma at baseline, 
received immunosuppressive medication, or if they had co-infections (HIV, HCV, HDV) or 
other liver diseases. The study conformed to the ethical guidelines of the 1975 Declara-
tion of Helsinki. Informed consent was obtained from all patients.
follow-up of participants
All subjects were monitored every 3-4 months. At every visit routine examination with 
biochemical (ALT, bilirubin, albumin, creatinin) and virologic (HBV DNA level, HBeAg, 
anti-HBe) assessments took place. Genotypic analysis was done in case of virologic 
breakthrough, defined as an increase in serum HBV DNA level > 1 log10 (10-fold) above 
nadir on at least two occasions after initial virologic response, or in case of serum HBV 
DNA > 4 log10 copies/mL at the end of follow-up. HBV genotype was determined at 
baseline in all patients.
endpoints
The primary outcome was virologic response (VR), defined as serum HBV DNA levels < 3 
log10 copies/mL during the on-treatment follow-up period. Secondary endpoints were 
loss of HBeAg for HBeAg-positive patients and emergence of ADV-related mutations.
laboratory tests
Serum alanine aminotransferase (ALT) levels were measured using automated tech-
niques. Hepatitis B surface antigen (HBsAg), antibody against HBsAg (anti-HBs), hepatitis 
B e antigen (HBeAg), and antibody against HBeAg (anti-HBe) were determined using a 
Microparticle Enzyme Immune Assay (MEIA, Abbott, Chicago, IL). Serum HBV DNA levels 
were measured using a previously described in house developed quantitative real-time 
polymerase chain reaction (PCR). 23, 24 Currently, this assay is multiplexed without com-
promising the lower limit of detection (373 copies/mL) with an internal control (pHHV) in 
order to control the process from DNA isolation through PCR. 25 To investigate resistance-
associated mutations related with ADV treatment, HBV DNA was extracted from serum 
samples using the MagnaPureLC (Roche Applied Science, Almere, The Netherlands) as 
described before and part of the HBV polymerase reverse transcriptase (domain A, B, C, D 
and F) was PCR amplified and sequenced directly, using a nested PCR. 23 The outer primers 
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were HT26-5 (3’-CAGGCCATGCAGTGGAA-5’) and YMDD2tripple (a combination of three 
primers to ensure the amplification of all genotypes, 5’-ACCCCATCTTTTTGTTTT-3’ + 
5’-ACCCCAACGTTTGGTTTTATTAGG-3’ + 5’- ACCCCATCTTTTTGTTTTGTTAGG-3’) amplify-
ing a PCR product of 880 bp and in the semi-nested PCR reaction the forward primer was 
replaced by HT26-2 (5’-CCTGCTGGTGGCTCCAGTTC-3’), amplifying a product of 806 bp. 
Sequencing was performed using Big Dye terminator v3.1 cycle sequencing kit (Applied 
Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) and a ABI3100 instrument (Applied 
Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Subsequently, sequence analysis 
was performed using Sequence Navigator software sequencer (Applied Biosystems), 
Lasergene v7 (DNASTAR, Madison, WI) and BioEdit Software (v7.05), Ibis Therapeutics, 
Carlsbad, CA, USA). The same region and procedure were used to determine HBV geno-
types. The consensus sequences for genotypes A-H were obtained from the GenBank.
data analysis
HBV DNA levels were logarithmically transformed for analysis. To correct for differences 
in reference between males and females, ALT levels are expressed as values representing 
a ratio to the local upper limit of normal (xULN). Continuous variables are expressed 
as means ± SD or median (range). Follow-up times were calculated from the date of 
ADV treatment initiation to the date of event or censorship. Cumulative probabilities 
of different endpoints were estimated by Kaplan-Meier analysis. The relative risk of 
several baseline and on-treatment parameters was estimated as an hazard ratio (HR) 
in an univariate and multivariate Cox’s proportional hazards model and presented with 
a 95 percent confidence interval (95%CI). Multivariate analysis was performed with 
all variables with a p -value < 0.2 in univariate analysis. As the low number of patients 
achieving both secondary endpoints did not provide enough power to include multiple 
variables, only univariate analysis was performed to assess baseline and on-treatment 
predictors. All statistical tests are two-sided, and a p-value < 0.05 was considered to be 
statistically significant. SPSS version 14.0 was used for all statistical analysis (SPSS Inc., 
Chicago, IL, USA).
resuLts
Baseline characteristics of the study population are presented in table 1. A total of 76 
patients treated with ADV monotherapy in our hospital were included in this analysis. 
Eighteen patients were excluded. Fourteen patients had a baseline HBV DNA < 4 log10 
copies/mL, of whom eight subjects were switched from a tenofovir (TDF)-containing 
regimen. One patient had coexisting auto-immune hepatitis, two patients were co-
infected with HIV, and one patient was co-infected with HDV. Of the 76 patients, fifty-
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seven (75%) subjects were men and the mean age was 46±14 years. Thirty-eight (50%) 
patients were HBeAg-positive, mean ALT was 3.8±4.2 xULN, and mean HBV DNA was 
7.5±1.6 log10 copies/mL. The most common genotypes were A (32%), B (16%), C (12%), 
and D (34%). Thirty (40%) subjects had a diagnosis of cirrhosis at baseline. Thirty-two 
(42%) patients received adefovir monotherapy as de novo treatment, while 27 (36%) 
and 42 (55%) patients were previously treated with (pegylated) interferon or lamivudine 
(LAM), respectively. Twenty-five (33%) patients had a prior history of LAM resistance. In 
fourteen (18%) patients LAM-resistant mutations could still be detected at the start of 
ADV treatment. Median follow-up was 122 (24-185) weeks.
Virologic response to adefovir
Overall, 42 (55%) patients achieved VR after a median follow-up of 23 (4-173) weeks, 
of whom 30 subjects (71%) maintained it throughout the on-treatment follow-up. In 
8 additional patients (19%) serum HBV DNA levels remained below 4 log10 copies/mL. 
The cumulative probability of achieving VR at 12, 24, 48, and 96 weeks was 11, 28, 39, 
and 49%, respectively (figure 1). Undetectable HBV DNA (<373 copies/mL) was demon-
table 1. Baseline characteristics of the study population (N = 76)
  
Age 46 ± 14
Gender (male %) 57 (75%)
Race
Caucasian 44 (58%)
Asian 19 (25%)
Other 13 (17%)
BMI 25 ± 4.1
ALT (*ULN) 3.8 ± 4.2
HBV DNA (log10 copies/ml) 7.5 ± 1.6
HBeAg-positive 38 (50%)
Genotype
A 24 (32%)
B 12 (16%)
C 9 (12%)
D 26 (34%)
Other 5 (7%)
Cirrhosis 30 (40%)
Previous treatment with peginterferon 27 (36%)
Previous treatment with lamivudine 42 (55%)
Patients with LAM resistance at baseline 14 (18%)
Patients with a prior history of LAM resistance 25 (33%)
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strated by only 19 (25%) patients during follow-up. Table 2 shows predictors of virologic 
response. Using multivariate analysis increased probabilities of VR were seen in HBV 
patients with HBeAg negativity at baseline (HR 2.98; 95%CI 1.24-7.19; p = 0.02), high 
baseline ALT levels (HR 1.11; 95% CI 1.05-1.18; p = 0.001), and low baseline HBV DNA lev-
els (HR 0.56; 95% CI 0.41-0.75; p < 0.001). In univariate analysis HBV DNA levels at week 
24 and 48 of ADV treatment were associated with VR as well, but both parameters did 
not reach statistical significance in multivariate analysis. Nevertheless, HBV DNA at week 
24 demonstrated a higher predictive value for VR than HBV DNA at week 48. Clear cut off 
points for both ALT and HBV DNA levels could not be found. Initial virologic response, 
defined as serum HBV DNA levels < 4 log10 copies/mL after 24 weeks of treatment 
26, was 
achieved in 35 (46%) patients, of whom 86% reached VR subsequently. Of the 41 patients 
who did not achieve initial virologic response, VR was found before week 48 and at the 
end of follow-up in two (5%) and twelve patients (29%), respectively. Seventeen patients 
(22%) demonstrated primary nonresponse, defined as a decrease in serum HBV DNA of 
less than 2 log10 after 24 weeks of treatment 
16, of whom four subjects (24%) showed VR 
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Figure 1. Kaplan-Meier curve for the cumulative probabilities of achieving virologic response, defined as 
HBV DNA < 103 copies/mL.
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at the end of follow-up. Of the patients with an HBV DNA decline of more than 2 log10 
after 24 weeks (59 subjects), only 64% achieved VR during follow-up.
serological response to adefovir
In total, eight of thirty-eight HBeAg-positive patients (21%) lost HBeAg during follow-up. 
Six patients also seroconverted to anti-HBe. The cumulative probability of HBeAg loss 
during ADV treatment was 10% after 48 weeks and 19% after 96 weeks of treatment. In 
none of the patients ADV was discontinued after HBeAg loss. One patient demonstrated 
a seroreversion during follow-up. In the univariate analysis, HBeAg loss was only associ-
ated with high baseline serum ALT levels (HR 1.15; 95% CI 1.02-1.31; p = 0.029).
table 2. Baseline and on-treatment predictors of virological response: time-to-event analysis
Parameters Univariate Cox PH model Multivariate Cox PH model
 HR (95%CI) p-value  HR (95%CI) p-value
Gender 0.70 (0.32-1.51) 0.36 - - -
Age (per 1 year increase) 1.02 (1.0-1.05) 0.05 - - -
Race
Caucasian 1.00 reference - - -
Asian 1.92 (0.97-3.82) 0.06 - - -
Other 1.14 (0.46-2.83) 0.78 - - -
BMI (per 1 unit increase) 0.96 (0.89-1.05) 0.38 - - -
Genotype
A 1.00 reference - - -
B 2.78 (1.18-6.58) 0.02 - - -
C 0.56 (0.16-1.95) 0.36 - - -
D 0.91 (0.43-1.94) 0.80 - - -
Other 1.06 (0.24-4.74) 0.94 - - -
HBeAg negativity 7.55 (3.39-16.8) < 0.001 2.98 (1.24-7.19) 0.02
Baseline HBV DNA (per log10 increase) 0.50 (0.40-0.64) < 0.001 0.56 (0.41-0.75) < 0.001
Baseline ALT (per 1*ULN increase) 1.06 (1.00-1.13) 0.05 1.11 (1.05-1.18) 0.001
Previous treatment
None 1.00 reference - - -
(PEG) IFN 0.96 (0.13-7.29) 0.97 - - -
Lamivudine 0.76 (0.34-1.71) 0.51 - - -
 (PEG) IFN/ Lamivudine 0.81 (0.39-1.65) 0.55
Lamivudine resistance at baseline 1.33 (0.63-2.81) 0.46 - - -
Prior history of lamivudine resistance 0.78 (0.40-1.55) 0.49 - - -
Viral load during ADV treatment
HBV DNA (per log10 increase) at week 24 0.48 (0.32-0.72) < 0.001 0.70 (0.47-1.03) 0.07
HBV DNA (per log10 increase) at week 48 0.33 (0.13-0.82) 0.02 - - -
Cirrhosis 0.73 (0.38-1.38) 0.33  - - -
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development of genotypic resistance to adefovir
Ten patients (13%) developed genotypic ADV resistance during a median follow-up 
of 122 (24-185) weeks of treatment. The cumulative probability of developing ADV-
resistant mutations was 3% and 8% after 48 and 96 weeks of treatment, respectively. In 
the univariate analysis, predictors of genotypic resistance were female gender (HR 4.99; 
95% CI 1.40-17.8; p = 0.013), a higher BMI (HR 1.18; 95% CI 1.02-1.37; p = 0.026), presence 
of cirrhosis (HR 6.54; 95% CI 1.39-30.9; p = 0.018), and not achieving VR during treatment 
(HR 6.60; 95% CI 1.35-32.4; p = 0.008). Furthermore, HBeAg positivity at baseline (HR 
3.09; 95% 0.79-12.0; p = 0.10), and HBV DNA levels above 3 log10 copies/mL after 24 and 
48 weeks of treatment exhibited a trend towards the emergence of ADV-resistant muta-
tions (table 3). No patients with genotype B or C developed genotypic ADV resistance.
Clinical outcome of patients with genotypic resistance
Table 4 shows a summary of the ten patients developing genotypic resistance during 
follow-up. Of these ten patients only three patients were initially switched to ADV after 
table 3. Predictors of development of genotypic adefovir resistance: time-to-event analysis (univariate 
Cox’s proportional hazards model)
Parameters HR (95%CI) p-value
Gender (female vs. male) 4.99 (1.40-17.8) 0.013
Age (per 1 year increase) 1.03 (0.98-1.09) 0.24
Race
Caucasian 1.00 reference
Other 0.44 (0.09-2.12) 0.30
BMI (per 1 unit increase) 1.18 (1.02-1.37) 0.026
Genotype
A 1.00 reference
D 3.51 (0.70-17.6) 0.13
Other 1.53 (0.20-11.5) 0.68
HBeAg positivity 3.09 (0.79-12.0) 0.10
Baseline HBV DNA (per log10 increase) 1.09 (0.71-1.66) 0.70
Baseline ALT (per 1*ULN increase) 0.93 (0.79-1.10) 0.41
Prior exposure to lamivudine 2.55 (0.53-12.3) 0.24
Lamivudine resistance at baseline 0.94 (0.19-4.82) 0.94
Prior history of lamivudine resistance 2.51 (0.66-9.63) 0.18
Cirrhosis 6.54 (1.39-30.9) 0.018
Not achieving VR 6.60 (1.35-32.4) 0.008
Viral load during ADV treatment
HBV DNA > 3log10 c/mL at week 24 7.15 (0.89-57.6) 0.07
HBV DNA > 3log10 c/mL at week 48 3.69 (0.76-17.8) 0.07
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LAM breakthrough. At baseline, seven patients were HBeAg positive, median serum 
HBV DNA level was 8.4 (5.2-9.4) log10 copies/mL, and median serum ALT level was 2.5 
(1.2-10.6) xULN. Eight patients had a diagnosis of cirrhosis. Median maximal viral sup-
pression was 3.9 log10 copies/mL. ADV-resistant mutations were detected at a median 
of 98 (36-177) weeks after treatment was initiated. At time of ADV resistance, median 
serum HBV DNA level was 5.1 (3.9-8.1) log10 copies/mL, and median serum ALT level was 
1.2 (0.6-2.5) xULN. Two patients had an episode of decompensation, and one of these 
patients died subsequently of liver failure. Specific ADV-resistant mutations included 
rtN236T and rtA181V (two patients), rtN236T (two patients), rtA181V/T (four patients), 
and rtV214A, rtQ215S/P (two patients). After detection of resistance, ADV was discon-
tinued in five patients, and four of these subjects were switched to entecavir. In one 
patient TDF/ LAM combination treatment was started. Two patients continued ADV and 
LAM was added. One patient did not receive salvage therapy. In this patient serum HBV 
DNA levels decreased and stabilized between 3-4 log10 copies/mL; ALT levels remained 
normal at continued ADV therapy. At the last follow-up visit ADV-resistant mutations 
could not be detected.
dIscussIon
In our study, 55% of patients demonstrated virologic response defined as serum HBV 
DNA levels < 3 log10 copies/mL, 21% of HBeAg-positive patients lost HBeAg, and 13% of 
patients developed ADV resistance during a median follow-up of 122 (24-185) weeks. 
HBeAg-negativity at baseline, high baseline serum ALT, and low baseline serum HBV 
DNA levels were independent predictors of VR. HBV DNA at week 24 was a better on-
treatment predictor of VR than HBV DNA at week 48. A diagnosis of cirrhosis at baseline 
and not achieving VR were the most important predictors of occurrence of ADV-resistant 
mutations.
It is known that a significant proportion of patients have slower and poor primary re-
sponses to ADV, probably related to the suboptimal approved dose. 14. As demonstrated 
by our and other studies in ADV- and LAM-treated populations, the most important 
baseline predictors of achieving VR are HBeAg-negativity, higher ALT, and lower HBV 
DNA levels. 26-29 Clear cut-off points for both ALT and HBV DNA levels could not be found 
in this study.
In contrast to the treatment of chronic hepatitis C virus infection, current official 
guidelines on the management of chronic HBV infection provides only few recommen-
dations on on-treatment evaluation. 16 Recently, a new strategy in the treatment with 
nucleos(t)ide analogues, the roadmap concept, was proposed. It was recommended 
that virologic response to ADV should be assessed at week 48 for both HBeAg-positive 
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and HBeAg-negative patients, as ADV has a delayed antiviral effect. 30 Indeed, Locarnini 
et al. showed that absolute HBV DNA levels above 3 log10 copies/mL after one year of 
therapy were predictors of ADV resistance at three years. 21 In our study, development 
of genotypic resistance also occurred more frequently in patients with HBV DNA levels 
above 3 log10 copies/mL after 48 weeks treatment. Probably due to the low number 
of patients with ADV resistance this association did not reach statistical significance 
(P=0.07). However, even more interesting is that this trend could already be found using 
absolute HBV DNA levels at week 24. In addition, viral load at week 24 demonstrated a 
higher predictive value for VR than HBV DNA levels at week 48, and only two patients 
who did not show initial virologic response at week 24, responded before week 48. Yet, it 
should be mentioned that baseline parameters of VR were far more important predictors 
of VR than on-treatment HBV DNA levels, as viral load at week 24 only demonstrated a 
trend and viral load at week 48 was not associated with VR at all in multivariate analysis. 
Nevertheless, our study suggests that on-treatment assessment of the efficacy of ADV 
can be done at an earlier stage than the usually recommended 48 weeks, thereby further 
optimizing the HBV roadmap concept.
Our study demonstrated that continued viral replication during treatment with an 
antiviral drug and presence of cirrhosis at baseline significantly increased the risk of 
antiviral resistance. Therefore, patients with cirrhosis might be a specific population 
for whom potent antiviral agents with high genetic barriers or even de novo combina-
tion therapy should be considered, as viral and biochemical breakthrough can result 
in severe exacerbations, decompensation, and death. 31 The reason why development 
of ADV resistance occurred more frequently in patients with cirrhosis remains unclear. 
Another unexpected finding was that prior lamivudine resistance was not significantly 
associated with the emergence of ADV-resistant mutations, as previous studies reported 
increased ADV-resistance rates in lamivudine-resistant HBV patients. 32 However, in our 
study 6 of 25 (24%) patients with a prior history of LAM-resistance showed ADV-resistant 
mutations during follow-up, which concurs with previously reported rates. 26, 33 This sug-
gests that the low number of patients with ADV-resistance did not allow demonstrating 
a significant relation between a prior history of LAM-resistance and development of ADV 
resistant mutations during ADV monotherapy.
Four patients who developed genotypic ADV resistance received entecavir mono-
therapy as salvage therapy, of whom three showed a rapid virologic response. In two 
patients LAM was added, and one patient was switched to TDF/LAM combination 
therapy. In vitro studies indicate that ADV-resistant HBV strains remain susceptible to 
ETV and TDF. 8, 34-37 These results were confirmed by anecdotal clinical reports. 26, 37, 38 In 
contrast, substitutions at rt181 associated with ADV-resistance may also induce a de-
creased susceptibility to LAM. 36, 37 The optimal antiviral salvage strategy for patients with 
ADV-resistant HBV remains, however, unclear and needs further investigation.
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Limitations of our study include the retrospective-observational design and the 
heterogeneous group of patients. Although this is may be considered a disadvantage, 
it probably also reflects the real situation of CHB clinical practice in the western world. 
Undetectable HBV DNA levels (< 300 copies/mL) may be a more precise definition of VR. 
However, as only few patients achieved undetectable HBV DNA, we decided to set the 
definition of VR at 103 copies/mL to be able to determine baseline and on-treatment 
predictive factors for achieving VR. In addition, using Kaplan-Meier analysis response 
rates can be overestimated. A basic assumption of this approach is that a patient will 
retain the measured outcome whether or not they remain in the study. However, relapse 
of HBV DNA levels above 103 copies/mL and seroreversion during treatment is known to 
occur in chronic HBV patients. 39
In conclusion, after two years of ADV treatment VR is achieved in approximately half 
of chronic HBV patients. HBV DNA levels at week 24 demonstrated a higher predictive 
value for VR than HBV DNA levels at week 48. In addition, emergence of ADV-resistant 
mutations occurred more frequently in patients with a viral load > 3 log10 copies/mL 
at week 24. Therefore, our study suggests that virologic response to ADV can already 
be assessed at week 24, instead of the generally recommended 48 weeks. Presence of 
cirrhosis at baseline and not achieving virologic response were important predictors of 
the occurrence of ADV-resistance associated mutations. Patients with cirrhosis at base-
line might be a specific population for whom more potent antiviral agents with higher 
genetic barriers or even de novo combination therapy should be considered.
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ABstrAct
The introduction of hepatitis B immunoglobulin (HBIg) prophylaxis has dramatically 
reduced the recurrence of hepatitis B viral infection after liver transplantation. However, 
lifelong HBIg therapy is inconvenient for the patient and very expensive. We studied the 
safety of discontinuation of HBIg therapy in the subset of liver transplant patients with 
fulminant acute hepatitis B.
Methods: The study included all patients with fulminant acute hepatitis B who were 
transplanted between 1991 and 2006 at the Erasmus Medical Center Rotterdam, 
received HBIg according to protocol, and completed at least one year of follow-up. 
Immunosuppression consisted of induction with monoclonal antibodies, steroids, and 
calcineurin inhibitors. Steroids were discontinued after three months; monotherapy 
with calcineurin inhibitors was continued after 3 months. HBIg was given for at least 12 
months before discontinuation.
Results: Nine patients (3 males/6 females) met the inclusion and exclusion criteria. Median 
follow-up was 86 months (range 23-199). Three patients received lamivudine in addition 
to HBIg. One and three year HBsAg recurrence rates were 0% and 11%, respectively. The 
one patient with HBsAg recurrence had a self-limiting course, became HBsAg negative 
again, and developed high levels of endogenous anti-HBs after reduction of immuno-
suppression in combination with lamivudine treatment. One patient died 23 months 
post-transplantation of a non-hepatic cause without any signs of HBV recurrence.
Conclusion: In patients transplanted for acute fulminant HBV infection, withdrawal of 
HBIg and lamivudine after one year appears to be safe with a low chance of HBV recur-
rence.
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IntroductIon
Orthotopic liver transplantation (OLT) is the only effective therapeutic option in patients 
with decompensated end-stage liver disease secondary to hepatitis B virus (HBV) infec-
tion. The management of patients after orthotopic liver transplantation for hepatitis B 
virus related hepatic failure has evolved tremendously during the past decades. Due to 
rapid and frequent recurrence of the disease, often with an aggressive course leading to 
graft failure and death, the overall survival of transplanted patients was initially low. 1, 2 
Based on this high rate of failure, hepatitis B infection became a contraindication for 
transplantation in many programs. The poor outcome was primarily due to re-infection: 
patients with HBV recurrence had a 1 and 3 year survival rate of 73% and 58%, respec-
tively, compared to 98% and 89%, respectively, for those without HBV recurrence. 3 Post-
transplant recurrence was drastically reduced by the introduction of passive intravenous 
(i.v.) immunoprophylaxis using hepatitis B immunoglobulin (HBIg), which is capable of 
preventing recurrence. 4, 5 Discontinuation of HBIg often results in HBsAg relapse and 
rapid graft failure. 6 Long-term treatment with HBIg, preferably combined with a nucleo-
side analogue, has therefore become the standard of care for HBV positive transplant 
recipients. 7
In patients transplanted for acute liver failure, recurrence rates were considerably 
lower than that seen in chronically infected patients. With long-term HBIg therapy recur-
rence rates in these patients are very low. 4, 8
Despite the advantages associated with HBIg treatment, long term HBIg therapy is 
both expensive and inconvenient for the patient. It has the theoretical disadvantage of 
being a plasma product and although it appears safe, toxicity over the long-term remains 
unknown. The high costs and the inconvenience of administration of intravenous HBIg 
prompted the development of intramuscularly administered HBIg, which reduced side 
effects and costs. 9, 10 Intramuscular therapy is as effective as intravenous administration 
and has become the most commonly used route of administration. 8 Additionally, stud-
ies showed the combination of HBIg with an oral nucleoside or nucleotide analogue to 
be more effective than either agent alone in the prevention of recurrence. 7, 11, 12
Patients with acute fulminant hepatitis receive the same prophylaxis as cirrhotic pa-
tients transplanted for decompensated chronic hepatitis B infection. However, patients 
with acute infection have a different, more vigorous immune response to the virus 
compared to the immune response in cirrhotic patients. There is almost no data on the 
efficacy and safety of HBIg discontinuation in patients transplanted for acute fulminant 
hepatitis B.
In our center, patients who receive hepatic transplant and have chronic hepatitis B 
virus infection receive life-long HBIg therapy. However, patients receiving orthotopic 
liver transplantation for an acute fulminant HBV infection discontinue HBIg therapy after 
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1 year. The HBV recurrence rate, graft survival, and patient survival for this group was 
investigated to determine the effect of HBIg cessation.
PAtIents And metHods
patients
Between the start of the program in 1985 and December 31, 2007, 559 liver transplan-
tations were performed at the Erasmus Medical Center Rotterdam. The Erasmus Liver 
Transplant Research database was used to identify eligible cases. Missing data were 
completed from medical records. Male and female patients, at least 16 years of age, who 
were transplanted for liver failure due to fulminant acute hepatitis B infection were eli-
gible. The use of nucleoside analogues in the pre-transplant and post-transplant period 
was allowed.
 Ninety-eight transplants (18%) were performed in 90 patients with HBV infection. All 
patients with fulminant hepatic failure due to acute hepatitis B were grouped together 
as acute hepatitis B. The diagnosis of acute hepatitis B required the presence of hepatitis 
B surface antigen (HBsAg in the serum) at the time of evaluation just prior to trans-
plantation or in the case of negative serum HBsAg, a viral load above 104 copies/ml in 
combination with the presence of IgM-antiHBc antibodies. Exclusion criteria included a 
follow-up period less than 12 months, no treatment with HBIg prophylaxis, concomitant 
use of interferon or other immune- or cytokine-based therapies directed against HBV, 
and organ or bone marrow transplantation other than the liver. Other exclusion criteria 
were liver disease not caused by hepatitis B, co-infection with hepatitis C, hepatitis Delta 
or human immunodeficiency virus (HIV), and flare of chronic hepatitis B presenting as 
“acute on chronic” disease. To exclude the latter diagnosis the explanted liver was exam-
ined by a pathologist.
The primary outcome measure was HBsAg recurrence in serum. Secondary end point 
was post-transplantation survival.
HbIg and lamivudine therapy
Patients transplanted after 1990 received HBIg (Hepatect, Biotest Pharma) 10.000 IU 
anti-HBs intravenously in the anhepatic phase and daily thereafter. Therapy was stopped 
if HBsAg was negative and anti-HBs >500 IU/l in HBeAg-positive patients and antiHBs 
>150 IU/l in HBeAg-negative patients. In patients transplanted after 2000 this was com-
bined with oral lamivudine 100 mg once daily with dose adjustment for kidney function. 
HBIg and lamivudine were stopped one year after transplantation per protocol.
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biochemical and virological assessments
HBsAg, anti-HBs, HBeAg, and anti-HBe were determined using a Microparticle Enzyme 
Immune Assay (MEIA, Abbott, Chicago, Ill). Serum HBV-DNA levels were determined by 
an in-house quantitative polymerase chain reaction, calibrated using Eurohep HBV DNA 
standards. 13 Used quantitatively, the Taqman assay enables accurate determination to 
levels of 1,000 copies/ml and has a lower detection limit of 400 copies per ml. 14
statistical analysis
Continuous variables were expressed as the median plus range. For all analyses, SPSS 
(Version 14.0.1; Chicago, IL, USA) was used.
resuLts
Fourteen patients underwent orthotopic liver transplantation for acute liver failure due 
to hepatitis B infection. Two of 14 patients (14%) were excluded, as they did not receive 
HBIg because this was not standard of care at the time of transplantation. Two patients 
were excluded because they had a follow-up of less than 2 months. One died as the re-
sult of graft failure, the other died due to intrapulmonary hemorrhage. One patient was 
excluded because he did not discontinue HBIg therapy per protocol. A total of 9 patients 
met the inclusion and exclusion criteria, including three males and six females with a 
median age of 39 years (range 19-62) (see Table 1). One patient was HBsAg negative at 
the time of transplant; this patient had an HBV-DNA of 104 copies/ml. In addition he had 
a serological profile and histology of the explanted liver compatible with fulminant HBV 
infection. Two of the nine patients were HBeAg positive. Median viral load was 2.596x104 
copies/ml (range 3.75x103 to 5.52x107). One of 9 patients received lamivudine in the 
pre-transplant period. After transplantation 3 out of 9 patients received a combination 
of HBIg and lamivudine.
Two patients (22%) had graft failure and were re-transplanted. One had acute graft 
failure immediately post-transplantation, and the second patient developed chronic 
rejection. Neither of these patients showed HBV recurrence in the period before or after 
re-transplantation. One patient (case 1) died after 23 months as a consequence of meta-
static ovarian carcinoma. She did not have recurrence of HBV during follow-up. Overall, 
the one and three year patient survival rates were 100% and 89%, respectively.
Recurrence rates were 0% and 11% after 1 and 3 years of follow-up, respectively. One 
patient had recurrence of HBsAg and viral replication 21 months post-transplant. HBeAg 
was negative and anti-HBe was positive; viral load was 8.51x105 copies/ml. The immune 
suppression at that time consisted of Cyclosporin 175 mg twice daily. Cyclosporin dose 
was temporarily reduced and lamivudine 100 mg once daily was added. Thereafter the 
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viral load declined rapidly below 103 copies/ml within 2 months and below the detec-
tion limit within 5 months; HBsAg disappeared after 5 months. No HBIg was adminis-
tered during this period and after 6 months lamivudine was discontinued. HBsAg and 
HBV DNA remained negative thereafter. Nine months after the recurrence low levels of 
endogenous anti-HBs were detected which increased to over 1000 IU/l in the months 
thereafter.
dIscussIon
Prophylaxis to prevent recurrent HBV infection following liver transplantation has dra-
matically improved the outcome for acute and particularly chronic hepatitis B patients. 
With the current prophylaxis regimes, combining HBIg with a nucleoside or nucleotide 
analogue, survival rates have increased dramatically. Survival rates are nowadays the 
same or even better in patients transplanted for HBV than in patients transplanted with 
a non-HBV diagnosis. 5 The dramatic increase in survival is mainly due to a diminished 
risk for HBV recurrence, which often ran an aggressive course leading to graft failure 
in a relative short period. 1-4 Our results confirm the excellent survival in patients trans-
planted for acute HBV, as the three-year survival rate was 89%. One patient died from a 
non-hepatic cause.
Despite the relatively good results of transplantation for HBV disease, questions re-
main regarding the optimal dose and duration of HBIg and lamivudine. Most transplant 
centers continue HBIg therapy indefinitely. Others report the same clinical outcomes 
with much lower doses of HBIg or administration for shorter periods of time. 15, 16
Our study differs from other studies as we specifically studied the discontinuation 
of immunoprophylaxis in a small group of well-characterized patients transplanted for 
acute fulminant hepatitis B. All patients had at least 1.5 years of follow-up and only one 
patient had a self-limiting recurrence of HBV.
Patients with acute fulminant hepatitis B differ from chronically infected patients in sev-
eral ways. One of the most important differences is the immune response to the virus. 
Patients with chronic hepatitis B mount an inadequate immune response, resulting in a 
situation in which the immune system tries to eliminate the virus but does not succeed 
in eradicating the infection, leading to ongoing liver inflammation. Patients with acute 
fulminant HBV infection mount a much more vigorous immune response, resulting in 
hepatic inflammation that is not adequately controlled and that ultimately leads to liver 
failure. As patients with acute hepatitis have an adequate immune response to HBV, the 
immune response may prevent recurrence in the majority of cases. Even in the event of 
post-transplant recurrence an adequate anti-HBV response is mounted, which was the 
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case in our patient with HBV recurrence. In this patient, treatment with lamivudine was 
started and the patient cleared the HBV infection and developed high levels of anti-
HBs.
Early discontinuation of HBIg can result in recurrence, as shown in chronic HBV pa-
tients receiving a course of less than 6 months HBIg. 4 The minimum duration of HBIg 
dosing, however, is not known. The majority of recurrences are seen in the first 2 years 
post- transplantation. 4, 8
In conclusion, our study suggests that in selected patients transplanted for acute 
fulminant HBV, HBIg prophylaxis can safely be discontinued after one year.
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ABstrAct
Chronic hepatitis B virus infection affects about 400 million people around the globe 
and causes approximately a million deaths a year. Since the discovery of interferon-α 
as therapeutic option the treatment of hepatitis B has evolved fast and the manage-
ment has become increasingly complicated. The amount of viral replication reflected 
in the viral load (HBV-DNA) plays an important role in the development of cirrhosis and 
hepatocellular carcinoma. The current treatment modalities for chronic hepatitis B are 
immunomodulatory (interferons) and antiviral suppressants (nucleoside and nucleotide 
analogues), which come with their own advantages and limitations. An overview of the 
treatment efficacy for both immunomodulatory as antiviral compounds is provided 
in order to provide the clinician insight in the factors influencing treatment outcome. 
With nucleoside or nucleotide analogues suppression of viral replication by 5-7 log10 is 
feasible, but not all patients respond to therapy. Known factors influencing treatment 
outcome are viral load, ALT levels and compliance. Many other factors which might 
influence treatment are scarcely investigated. Identifying the factors associated with 
response might result in stopping rules, so treatment can be adapted in an early stage 
to provide adequate treatment and avoid the development of resistance. The efficacy 
of compounds for the treatment of mutant virus and the cross-resistance is largely un-
known. However genotypic and phenotypic testing as well as small clinical trials provided 
some data on efficacy in this population. Discontinuation of nucleoside or nucleotide 
analogues frequently results in viral relapse, however some patients have a sustained 
response. Data on the risk factors for relapse are necessary in order to determine when 
treatment can be discontinued safely.
In conclusion: chronic hepatitis B has become a treatable disease, however much re-
search is needed to tailor therapy to each individual patient, to predict the sustainability 
of response and determine the best treatment for those failing treatment.
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IntroductIon
Treatment of chronic hepatitis B remains an important clinical objective. Estimates are 
that 2 billion people have been infected worldwide and chronic hepatitis B currently 
affects about 400 million people, particularly in developing countries. 1 Chronic hepatitis 
B is responsible 500,000 to 1.2 million deaths annually from liver cirrhosis and hepato-
cellular carcinoma (HCC). 2 It is one of the most common infectious diseases and among 
the world’s leading causes of death. There are two strategies to decrease these numbers, 
prevention of new infections and treatment of those already chronically infected. Treat-
ment options consist of immunomodulatory and viral suppressant drugs. In this review 
the current standard of care and the future developments in the field of chronic hepatitis 
B are discussed.
WHAt Is tHe oPtImAL treAtment
naïve patients
The ideal treatment for hepatitis B is an effective cheap treatment, resulting in HBsAg 
loss and formation of anti-HBs, with finite treatment duration and little side effects. Cur-
rently none of the HBV treatments fulfil these conditions. With interferon based therapy 
HBsAg loss occurs in 3%-10% of the patients within one year of the start of therapy and 
increases in sustained responders to 11%-32%. 3-9 HBsAg loss is rare (<2% after one year 
of treatment) in patients treated with nucleos(t)ide analogues, which is about the rate 
observed in the natural history of the disease. 10-16 However in a small cohort treated 
with tenofovir, HBsAg loss was observed in 14% of 35 patients. 17 More large size trials 
have to be conducted to investigate the rate of HBsAg loss for the newer nucleos(t)
ide analogues or their combinations. Treatment with Interferon-α or PEG-interferon-α 
treatment is of finite duration and response is often durable off-treatment. However this 
treatment has side effects and only a minority responds to it. Nucleosides/nucleotides 
are well tolerated and most patients respond to therapy but treatment is hampered by 
the selection of drug resistant mutants leading to loss of efficacy and frequent relapse 
after discontinuation. As none of the current registered therapies for chronic HBV is 
ideal, none of the drugs is regarded as the standard first-line therapy for HBV. Strategies 
have particularly aimed at selecting host and virus characteristics either before or dur-
ing therapy to increase treatment efficacy and also withdraw ineffective treatments. The 
argument about the poor tolerability of interferon has been weakened by the introduc-
tion of PEG-interferon-α, which only has to be administered once a week. Furthermore it 
is believed PEG-interferon-α is more potent than the conventional interferons, however 
good comparative studies have not been performed. 18 Based on treatment outcomes, 
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the preferable treatment shifts to interferon based therapy or nucleoside/nucleotide 
analogue therapy for different patient groups. In Table 1 the known predictors for re-
sponse are given for both interferon-α based therapies or nucleos(t)ide analogues.
Recent studies found a strong correlation between HBV DNA level and the development 
of liver cirrhosis and HCC. However, as none of the studies concerning natural history 
separately analysed the outcome in patients with prolonged normal aminotransferases 
the exact influence of the viral load is not known. 19-21 Interferon based therapies are 
generally ineffective in patients with low pre-treatment serum aminotransferases levels, 
and for these patients nucleoside/nucleotide treatment would be indicated. Low pre-
treatment serum aminotransferases and high HBV DNA levels also decrease the likeli-
hood of response for these agents, however this confers to HBeAg loss/seroconversion. 
In theory nucleoside/nucleotide analogues are effective in lowering the viral load and 
thereby decreasing the risk for the development of cirrhosis and HCC. 22
However the benefit of this approach on survival is not supported by clinical trials.
For therapy of treatment naïve patients with elevated ALT levels, consensus guidelines 
have no preference for interferon or nucleoside/nucleotide therapy. Treatment outcomes 
for different therapies are provided in Table 2. Genotype proved to be an important 
predictor for the response to interferon-α or PEG-interferon-α therapy, especially in 
HBeAg positive patients. Genotype A and B show superior end off-treatment responses 
as well as off-treatment responses compared to genotypes C and D. 3, 4, 18, 23-25 HBeAg loss 
occurred in 34-36% of patients. In addition HBsAg seroconversion was observed in 13-
22% of patients with genotype A. 18, 26, 27 Therefore a 48 week course of PEG-interferon-α 
should be considered as first-line therapy for HBeAg positive patients with genotype A 
or B.
 For HBeAg negative patients the distinctions are less clear. Genotype D responds less 
to PEG-interferon-α compared to genotypes A, B or C. Sustained ALT normalisation and 
treatment Increased likelihood of response decreased likelihood of response
(PEG)interferon Baseline ALT >2 ULN 28, 148, 149 Baseline ALAT <2 ULN 28, 148, 149
Baseline HBV DNA <109 c/ml 4, 28 Baseline HBV DNA >109 c/ml 4, 28
Genotype A or B Genotype C or D
Longer treatment duration 34-36, 150
Nucleoside/
nucleotide analogues
Baseline serum aminotransferases >2 
ULN 151, 152
Baseline serum aminotransferases <2 151, 152
Baseline HBV DNA <109 c/ml 151 Baseline HBV DNA >109 c/ml 151
table 1. Baseline factors influencing likelihood of response to antiviral therapy. ULN = upper limit of 
normal; c/p = copies/ml.
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a viral load <20,000 copies/ml was observed in 27%, 44%, 52% and 16%, for genotype 
A, B, C and D respectively. Sustained response occurred significantly more frequent 
in genotype B and C compared to genotype D. The difference in sustained response 
between genotype A and D was not significant, probably due to the small number of 
genotype A infected patients. 28 However only patients with genotype A, treated with 
PEG-interferon-α for 48 weeks, had a considerable chance (18%) to develop HBsAg sero-
conversion. 27 The long-term follow-up is not known for PEG-interferon-α. Two years of 
follow-up showed a decrease in response (HBV DNA <2.0x104 copies/ml) from 43% after 
24 weeks of follow-up to 29%. 29 However long-term follow-up studies with conventional 
interferon showed high relapse rates. 2, 5, 30 Nucleos(t)ide analogues are effective across 
all genotypes in both HBeAg positive and HBeAg negative patients and have proven 
to be a good treatment option for chronic active hepatitis B. 31, 32 However recent data 
suggest a role of genotype in treatment outcome, not related to resistance. Patients with 
genotype B or D more frequently relapsed when switched from tenofovir to adefovir. 
The numbers are small, but warrant further investigation. 33
retreatment of non-responders
Treatment of non-responders to previous treatment is little studied and most studies 
are of small size. Studies show that retreatment with conventional interferon can induce 
HBV DNA loss and HBeAg seroconversion, however the overall results are not conclusive 
(Table 3) Most of the results are difficult to interpret as the initial schedules of interferon 
therapy differs as well as the time to retreatment. The retreatment schedules often differ 
from the initial schedule, and treatment duration is often prolonged influencing treat-
ment outcome positively. 34-36 The real benefit of interferon retreatment, especially with 
pegylated interferon is unclear. Nucleos(t)ide analogues appear to be effective in inter-
feron failures, although efficacy may be different and data are limited. 37 A clinical trial 
using adefovir dipivoxil included 123 HBeAg positive and 48 HBeAg negative patients 
failing prior interferon therapy. HBeAg seroconversion rates were similar for interferon 
naïve and experienced patients. 38 The efficacy of the use of interferon for lamivudine 
failures is unclear. (Table 3 and 4) It appears that interferon is effective in patients who 
received lamivudine, but did not develop resistance. Interferon-α therapy probably 
has a low efficacy in lamivudine resistant patients, though the numbers published are 
small. 39, 40
Cirrhotic patients
The life expectancy of patients with cirrhosis, if untreated, is greatly diminished with a 
5-year survival of 84% for compensated and 14-35% for decompensated cirrhosis. 41-43 
Interferon has to be used with caution in cirrhotic patients and its use is limited to Child 
A cirrhosis. Interferon may be effective in compensated cirrhotics in which treatment 
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Author; Journal; year HBeAg 
loss 
(%)
HBeAg 
serocon-
version 
(%)
HBsAg 
loss 
(%)
decline 
viral load 
(log10 
copies/
ml)
HBV dnA 
negativ-
ity (%)
ALt 
normali-
sation 
(%)
Histo-
logical 
improve-
ment (%)
resistance 
(%)
HBeAg pos
PEG-IFN-α 2a Cooksley; J. Viral Hepatitis; 
2003 18 $
35 33 39 9 35
PEG-IFN-α 2a Lau: NEJM; 2005 4 34 32 3@ 2.4 14 4 41 49
PEG-IFN-α 
2b
Janssen; Lancet; 2005 3 36 29 7 2.3 7 4 32 53*
lamivudine Chang; NEJM; 2006 13 20 18 1 5.4 36 2 60 62 13
lamivudine Alexander; BMC Gastroenter; 
2005 153
42 28 56 10
lamivudine Chan; Ann Intern Med; 2005 
154
28 28 0 2.74 10 1 78 59 ** 40
lamivudine Yao; Hepatobil Pancr Dis Int; 
2004 155
10 8 36 72 12
lamivudine Jonas; NEJM; 2002 156 26 2 61 6 55 19
lamivudine Mazur; Med Sci Monit; 2002 
157
49 44 5 37 8 56
lamivudine Barbaro; J Hepatol: 2001 158 19 0 23 27* 16
lamivudine Dienstag; NEJM 1999 48 32 17 2 44 7 41 52* 32
lamivudine Gane; J Hepatol; 2006 64 23 21 5.5 40 2 75 56 8
adefovir Marcelin; NEJM; 2003 16 24 12 3.6 21 4 48 53 0
adefovir Lee; Hepatology; 2006 104 14 4.0 29 5 79 0
adefovir † Zheng; Hepatology; 2006 127 13 8 0 4.5 28 2 79 0
adefovir Bzowej; Hepatology; 2006 66 20 18 5.7 39 2 81 2
entecavir Chang; NEJM; 2006 13 22 21 2 6.9 67 2 68 72 0
telbivudine Gane; J Hepatol; 2006 64 26 22 6.5 60 2 77 65 3
telbivudine Bzowej; Hepatology; 2006 66 31 27 6.6 58 2 77 4
HBeAg neg
PEG-IFN-α 2a Marcellin; NEJM; 2004 5 4 2.3 19 4 59 59
lamivudine Marcellin; NEJM; 2004 5 0 4.2 73 4 73 58^ 41
lamivudine Lai; NEJM; 2006 15 0 4.5 72 2 71 61 6
lamivudine Lai; NEJM; 1999 16 0 72 56* 14
adefovir Hadzyannis; NEJM; 2003 14 3.9 51 4 72 64 0
entecavir Lai; NEJM; 2006 15 0 5.0 90 2 78 70 0
Mixed
lamivudine Ooga; J Gastroenterology; 
2004 159
78 5 78 16
lamivudine Suzuki; Intervirology; 2003 
111
42 28 0 88 6 86
lamivudine Yao; J Hepatology; 2006 65 18 4.3 43 2 78
entecavir Yao; J Hepatology; 2006 65 15 5.9 76 2 90
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outcomes do not differ from those without cirrhosis. 6, 34, 36, 44, 45 Adverse events, dose 
reductions and early discontinuation occur more frequently in cirrhotic patients. 46, 47 
Nucleos(t)ide analogues appear to be as effective in cirrhotics as in those without cir-
rhosis regardless of HBeAg status. 48-50 Lamivudine treatment in patients with advanced 
fibrosis or compensated cirrhosis reduced the progression of liver disease. Loss of efficacy 
due to resistance resulted in an increase of disease progression.51 Entecavir treatment 
resulted in undetectable HBV DNA loss (LLD 300 copies/ml) in >90%, ALT normalisation 
in over 60% and histological improvement in >70% of patients with compensated cir-
rhosis. 52
Decompensated cirrhotic patients should be treated with nucleoside analogues as 
interferon-α is contra-indicated. 53, 54 The timing of the initiation of therapy is essential. If 
the bilirubin level rises above 3.5 mg/dl the 3 month survival is poor and is not likely to 
be influenced by nucleos(t)ide analogue therapy. Several studies confirmed the efficacy 
of lamivudine therapy in patients with HBV related decompensated cirrhosis. Therapy 
resulted in a significant improvement in virological, biochemical and markers of disease 
status. 55-59
Treatment of lamivudine refractory patients, wait-listed for liver transplantation, with 
adefovir for 48 weeks in resulted in a 4.1 log10 copies decline in viral load. Liver functions 
improved significantly and the Child Pugh-Turcotte score (CPT) improved or remained 
stable in 92% of the patients. 60 Adefovir therapy initiated in pre-transplant patients 
resulted in undetectable serum HBV DNA in 76% and normal ALT in 84% of the patients 
after 96 weeks of treatment. Markers of synthetic liver function improved in most pa-
tients, the Child-Pugh scores improved, or remained the same and survival was over 80% 
after two years. 61 Another study in lamivudine refractory patients with decompensated 
cirrhosis showed a HBV DNA response (≤105 copies/ml or ≥2 log decrease from baseline) 
in 92%, over half of the patients had ALT normalisation and there was improvement of 
table 2. Treatment outcomes after 1 year of treatment for different antiviral drugs for the management 
of chronic hepatitis B. Although conventional interferon-α is widely used for the treatment of HBV it is not 
listed as this treatment will be replaced by PEG-interferon-α in the near future. Efficacy measures for PEG-
interferon presented are off-treatment responses after 24 weeks of follow-up. Studies are organised by 
HBeAg status and the mixed studies included both HBeAg positive as HBeAg negative patients.
* only improvement of ≥2 points in necroinflammation according to Ishak
** only improvement of ≥2 points in necroinflammation according to Knodell
@ HBsAg seroconversion
$ treatment duration 24 weeks
^ After 24 weeks of follow-up
Lamivudine study performed in children
† Including some Lamivudine resistant patients
1 LLD 200 copies/ml 4 400 copies/ml 7 1.0x106 copies/ml
2 LLD 300 copies/ml 5 5.0x103 copies/ml 8 1.4x106 copies/ml
3 LLD 366 copies/ml 6 7.0x105 copies/ml 9 5.0x106 copies/ml
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liver synthesis function and Child-Pugh scores after one year of treatment. 62 Although 
it is possible to inhibit viral replication and prevent clinical decompensation, the oc-
currence of HCC is not prevented. After 5 years of continuous lamivudine therapy or 
add-on therapy with adefovir in lamivudine resistant cases in HBeAg negative cirrhotic 
patients, 16% of patients died, or underwent liver transplantation. However 24% was 
diagnosed with HCC. 63 The moment of initiation of nucleos(t)ide analogues to prevent 
the occurrence of HCC has yet to be determined. In cirrhotic patients there seems no 
benefit, but a study including patients with advanced liver fibrosis or cirrhosis showed 
a reduction in HCC in lamivudine treated patients compared to placebo. Patients with 
lower fibrosis and Child-Pugh scores were less prone to disease progression. 51 The data 
suggest nucleos(t)ide analogue therapy has to be initiated before the cirrhosis develops 
to prevent HCC and has to be continued indefinitely. 51, 63
treAtment WItH nucLeosIde/nucLeotIde AnALogues
Four oral nucleoside or nucleotide analogues, lamivudine, adefovir, entecavir and tel-
bivudine, are currently marketed and approved as first line therapy for the treatment 
of chronic hepatitis B. All therapies result in reduction of viral load, ALT levels and 
improvement of liver histology. (Table 2) It is difficult to point out one compound which 
should be the first nucleoside or nucleotide used for the treatment of chronic hepatitis 
B. At least two major points at least have to be taken into account: (i) efficacy of the 
treatment on the short and long term, including the development of resistance and (ii) 
the costs. Comparing the efficacy of treatment is difficult, however some comparative 
studies have been performed. Both entecavir and telbivudine, proved superior efficacy 
over lamivudine after 1 year of treatment. 13, 15, 64, 65 Direct comparison of telbivudine or 
adefovir for 52 weeks showed superior efficacy on viral and biochemical parameters for 
telbivudine, but resistance was not assessed. 66 Adefovir was never directly compared 
to lamivudine. Direct comparison of entecavir and adefovir for a duration of 24 weeks 
showed a decline of HBV DNA of 6.97 log10 copies/ml for entecavir and 4.84 log10 cop-
ies/ml for adefovir. PCR undetectability (HBV <300 copies/ml) was reached in 45% of 
entecavir treated patients vs. 13% of those receiving adefovir. 67 Tenofovir seems to be a 
promising new drug, but it has only been used in small series in lamivudine or adefovir 
treatment failures. The long term outcomes are only known for lamivudine and adefovir. 
Another problem with interpretation and positioning of the outcomes of clinical studies 
is the lack of standardisation of outcome measures.
The development of resistance is the most important factor for loss of efficacy. Lami-
vudine has a high rate of resistance of 18-27% after 1 year and this increases over time, 
being 44% at year 2, 60% at year 3, and after 4 years of treatment almost 70% has devel-
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oped resistance. 5, 68-74 Adefovir showed no resistance after 1 year, but rates increased to 
1-3%, 11%, 18% and 28% at year 2, 3, 4 and 5. 14, 16, 75 Entecavir showed no resistance up 
to 2 years of treatment, however complete non-responders did not receive treatment in 
year 2. 76 Telbivudine had a resistance rate of 2-4% after 1 year of treatment. 64, 66
 With long-term lamivudine treatment HBeAg seroconversion increases to 27%, 40%, 47% 
and 50% at years 2, 3, 4 and 5 respectively, despite the development of resistance. 68, 72, 74, 77 
Prolonged therapy with adefovir in HBeAg positive subjects resulted in viral load below 
103 copies/ml in 28% at year one, 45% and 56% at years 2 and 3. ALT levels became 
normal in 48%, 71% and 81% after 1, 2 and 3 years of treatment. Rates of HBeAg-loss 
increased to 42% and 52% and HBeAg seroconversion rates increased to 29% and 43% 
at year 2 and 3. 78 A study with continued treatment up to 2 years showed an increase 
in viral reduction from -4.5 to -5.0 log10 copies/ml, increased PCR-negativity (lower limit 
of detection 300 copies/ml) from 28% to 42%, but the percentage of ALT normalisation 
remained unchanged (79% to 78%). The percentage HBeAg-loss increased from 13% to 
19% and the percentage of patients with HBeAg seroconversion increased to 15%. 79 In 
HBeAg negative subjects prolonged adefovir therapy of 2 years, showed little additional 
decline in viral load, but consolidated the response to adefovir, as 71-75% of the patients 
had a viral load below 103 copies/ml and ALT normalisation in 73-79%. Long term treat-
ment up to 5 years resulted in a viral load below 103 copies/ml in 78-79% at year 3, 
65-68% at year 4 and 67% after 5 years of continuous treatment. ALT levels were normal 
in 69-78% at 3 years, 70-75% at 4 years and 69% after 5 years. 75 Treatment with adefovir 
in an open population resulted in less favourable results, as during a mean follow-up 
of 115 weeks only 55% had a viral load below 103 copies/ml. Twenty one percent of 
HBeAg positive patients lost HBeAg. 80 Entecavir also showed a continuous viral decline 
in patients with detectable HBV DNA beyond week 48 and HBeAg seroconversion rates 
increased. 81, 82 Another aspect which is little studied is the sustainability of response 
after discontinuation of therapy. In HBeAg positive subjects who seroconverted during 
therapy, response is durable in over half of the subjects. 13, 83-86 In HBeAg positive patients 
treated with lamivudine who discontinued after achieving a complete response (HBeAg 
loss, undetectable HBV DNA and normal ALT) had a sustained response of 78%, 72%, 
70%, 67% and 64% after 1, 2, 3, 4 and 5 years of follow-up respectively. 87 In HBeAg 
positive subjects with HBeAg seroconversion during adefovir therapy the response 
was sustained in 91%. 86 In entecavir treated HBeAg positive subjects for 48 weeks the 
sustained response (HBeAg loss and HBV DNA <7.0x105 copies/ml) was 82% after 24 
weeks follow-up. 88 The durability can be increased by continuing treatment for several 
months after HBeAg seroconversion. Therefore it is recommended to continue treat-
ment for at least 3-4 months. 84, 85 As many clinical trials had a predetermined endpoint, 
sustainability migt be a bit higher if treatment was continued for a longer period in those 
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patients who underwent HBeAg seroconversion within 3 months before dicontinuation. 
In HBeAg negative subjects the durability of response is often poor. Patients treated for 
two years with lamivudine who had undetectable HBV DNA levels (LLD 200 copies/ml) 
discontinued treatment. After 12 months of follow-up the virological relapse rate was 
50%. 89 The viral load at discontinuation and duration of treatment do not accurately 
predict sustainability of response in HBeAg negative patients.
Other parameters such as intrahepatic total HBV DNA and intrahepatic cccDNA and 
HBcore expression and the level of hepatitis B virus core related antigen appear to 
be superior in prediction of sustained response compared to viral load at the end of 
therapy. The studies where however small and the results have not been confirmed by 
others. 90, 91
management of treatment failures to nucleos(t)ide analogues
A distinction can be made for patients failing therapy: due to resistance or other reasons. 
Many patients do not achieve complete suppression of HBV DNA during treatment. 
Several factors may contribute such as non-compliance, inefficient conversion from the 
prodrug to its active metabolite, inadequate phosphorylation within the hepatocytes 
or underdosing of the drug. Some patients failing to respond initially to treatment may 
already harbour a resistant mutant prior to the start of therapy. 92, 93 Underdosing is 
particularly an issue with adefovir treatment as the 10 mg dose was chosen for safety 
reasons. The 30 mg dose was more effective, but also more nephrotoxic. 16
Little is known why some patients have suboptimal viral suppression. The known 
baseline predictors for response provide information on the likelihood of response, but 
the outcome cannot be predicted. (Table 1) A high baseline viral load is probably one of 
the reasons why more HBeAg-positive patients have a suboptimal response compared 
to HBeAg-negative patients. 13-16 Recently genotypic dependent polymorfisms have been 
described associated with primary treatment failure and more might be detected. 93, 94 
As viral factors, as well as host factors play an import role in response, it is difficult to 
assess the optimal treatment for sub-optimal responders. Presuming study randomisa-
tion led to an equal distribution of both viral and host factors, it is to be expected that 
more potent drugs are able to suppress viral replication in subjects with suboptimal 
suppression. Entecavir and telbivudine proved their superior potency over lamivudine 
in a head to head comparison and for telbivudine this observation was also been made 
in comparison with adefovir. 13, 15, 64-66 In adefovir treatment failures the more potent 
drug tenofovir showed good viral suppression. 95 Patients responding to tenofovir and 
switched to adefovir showed viral relapse, while no mutants could be detected. 33, 96 An-
other strategy could be adding a second drug to the failing compound. In vitro testing 
demonstrated that combining adefovir with an L-nucleoside (lamivudine, telbivudine, 
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emtricitabine) exerted additive antiviral effects. 97 Clinically the combination of adefovir 
and emtricitabine resulted in stronger viral suppression. 98 In patients failing adefovir 
switching therapy to tenofovir and either emtricitabine or lamivudine resulted in de-
crease in viral load in most patients. 99
prevention of resistance
For nucleoside/nucleotide analogue treatment, a number of risk factors for resistance 
have been identified. For lamivudine this includes: prior course of lamivudine, duration 
of lamivudine therapy, high body weight and body mass index, male sex and high 
baseline HBV DNA, insufficient HBV DNA suppression at month three, and elevated ALT 
levels during treatment. 100-102 For adefovir the following risk factors for resistance have 
been reported: lamivudine resistance at start of treatment, high baseline viral load, <1 
month continuation of lamivudine after the start of adefovir therapy in case of lami-
vudine resistance, insufficient HBV DNA suppression during treatment. 103-105 For ente-
cavir, lamivudine resistance and suboptimal suppression of HBV DNA on treatment were 
found as risk factors. 76 A key factor in the development of resistance is the persistence of 
viral replication. Several studies found a relation between ongoing viral replication and 
the development of resistance. Patients with a serum HBV DNA >103 copies/ml after 6 
months of lamivudine treatment had a 63% chance for developing resistance. 102 Another 
study in 24 patients, found that none of the subjects with excellent viral suppression 
(nadir HBV DNA <50 copies/ml), two out of 5 patients with a nadir viral load between 
50-300 copies/ml and all 11 patients with a nadir viral load >300 copies/ml developed 
resistance. 101 For adefovir, a load of over 105 copies/ml after 48 weeks of treatment is a 
risk factor for resistance. 105 Patients treated with adefovir not having a viral load below 
104 copies/ml at week 12 or 24 had a low probability of reaching virological response 
and had an increased risk for the development of resistance. These patients should be 
switched to alternative treatment.80 In a study in which patients were treated with either 
telbivudine, or lamivudine, a viral load >103 copies/ml after 24 weeks of treatment was 
associated with an increase risk for resistance. Although entecavir has a high genetic 
barrier slowing down the development of resistance, ongoing viral replication is a major 
risk factor for its occurrence. Even in patients with good viral suppression mutants can 
appear in the background resulting in viral relapse.106
The role of genotypes is controversial as some have reported influence of the genotype 
on the development of resistance, while others do not find this association. 103, 107-114 For 
adefovir genotype D appears to be associated with an increased risk for resistance. 103 
Genotype might influence the mutational pattern. When genotype A and D in lamivudine 
resistant patients were compared, the rate of M204V mutants and rates of mutations at 
position rtL180 was higher in genotype A. The rate of M204I mutations was higher in 
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genotype D. The median time of shift from M204I to M204V was shorter in genotype A. 
Additional resistance associated mutations were only detected in patients infected with 
genotype D. 115 In genotype C patients HBV DNA was significantly higher compared to 
genotype B after the development of YMDD mutants. 107 Studies are often hampered by 
their small size. For compounds with a low rate of resistance it is hard to determine the 
role of the genotype as large numbers have to be treated often for a prolonged period.
The current strategy of continuous monotherapy is insufficient to completely suppress 
viral replication in a large number of patients . In vitro testing has to be done in order 
to find promising combinations of drugs. These combinations of drugs then have be 
to investigated in long-term large scale trials with clinical response and resistance as 
outcome measures. 97
It is important to detect resistance as early as possible during treatment with nucleoside 
or nucleotide analogues. In case of virological breakthrough, which is generally agreed 
to be a 1 log10 increase in viral load in either in copies/ml or IU/l after an initial response 
in compliant patients. 116-118 Sensitive quantitative HBV DNA assays are therefore advised 
for monitoring, as a viral rebound can be detected earlier. Virological breakthrough 
mostly precedes biochemical breakthrough and the time lapse may vary from weeks to 
months. 119 Genotypic testing provides information on the type of mutation which arises 
during treatment and if there might be decreased drug sensitivity. Knowledge of the 
specific mutation will be increasingly important in the future as different mutations may 
have a distinct influence on treatment efficacy of other compounds. Newly detected 
mutations should be investigated by phenotypic assays to determine their replication 
fitness and susceptibility to other compounds. 120
mAnAgement oF resIstAnce
Lamivudine resistance
Adefovir has proven to be effective against lamivudine resistant mutants. Adefovir 
monotherapy is able to suppress viral load by 2.4-4.0 log10 copies/ml. 
104, 121 The data of 
adefovir and lamivudine combination therapy by adding adefovir to ongoing lamivu-
dine is controversial. A randomised study found no difference in viral decline. 121 Another 
study did not find a difference in viral suppression after one year of treatment, but at 
month 18 adefovir and lamivudine showed a stronger viral decline (4.3 log10 copies/
ml) vs. adefovir monotherapy (3.4 log10 copies/ml). 
122 A study comparing combination 
therapy to monotherapy in lamivudine resistant patients showed significantly higher 
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n Author; Journal; year HBeAg 
loss 
(%)
HBeAg 
sero-
conver-
sion 
(%)
HBsAg 
loss 
(%)
decline 
viral 
load 
(log10 
copies/
ml)
HBV 
dnA 
nega-
tivity 
(%)
ALt nor-
malisation 
(%)
Histo-
logical 
improve-
ment 
(%)
resis-
tance 
(%)
HBeAg pos
PEG-IFN-α 2b
16 Leemans; J Hepatology; 
2006 39
13 13 6 0.6 6 4 19
adefovir 45 Buti; Hepatology; 2004 168 13 0 33 7 51
adefovir
19 Peters; Gastroenterology; 
2004 121
16 11 4.0 26 5 47 0
HBeAg neg
PEG-IFN-α 2b 20 Vassiliadis; WJG; 2006 40 5 4 10
adefovir 75 Buti; Hepatology; 2004 168 0 51 7 63
adefovir
20 Manilakopoulos; Hepatol-
ogy; 2005 122
3.3 72 5
adefovir + lami-
vudine
44 Manilakopoulos; Hepatol; 
2005 122
3.3 87 0
adefovir
26 Koskinas; J Hepatology; 
2005 169
2.5 92 4
adefovir+ lami-
vudine
74 Lampertico; Hepatology; 
2005 170
78 6 82 0
adefovir + lami-
vudine
23 Koskinas; J Hepatology; 
2006 169
2.8 87 0
adefovir + lami-
vudine
49
Vassiliadis; AP&T; 2005 171 0 6.5 57 4 75
Mixed
adefovir
18 van Bömmel; Hepatology; 
2004 17
19 0 2.8 44 4
adefovir + lami-
vudine
20 Peters; Gastroenterology; 
2004 121
17 6 3.6 35 5 53 0
adefovir 57 Lee; Hepatology; 2006 104 20 2.4 19 3 60 18
adefovir + lami-
vudine
46 Perrillo; Gastroenterology; 
2004 62
15 8 0 4.6 20 1 30
adefovir ± lami-
vudine ‡
126
Schiff; Hepatology; 2003 60 4.1 81 4 76 0
adefovir + lami-
vudine
34 Moriconi; J Hepatology; 
2006 172
68 1
adefovirr ± 
lamivudine
65 Hann; J Hepatology; 2006 
135
7 †† 2.4 21 5
entecavir
42 Chang; Gastroenterology; 
2005 173
11 4 5.6 26 4 68 0
entecavir
141 Sherman; Gastroenterology; 
2006 132
10 11 5.1 27 2 61 55 7
entecavir
42 Karino; J Hepatology; 2006 
174
15 3.8 60 4 78 60 0
entecavir 116 Yao; J Hepatology; 2006 175 8 6 5.8 27 2 85
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rates of PCR-negativity (81% vs 40%) in patients with a baseline viral load ≥5 log10 cop-
ies/ml. 123
Although adefovir is effective for the treatment of lamivudine refractory patients 
there seems to be some degree of cross-resistance as in vitro testing shows a 2.8-16 
fold increase in IC50 values for adefovir for lamivudine resistant strains. 
124-126 Clinically 
mutations also associated with lamivudine resistance appear to influence treatment 
outcomes. Viral decline and ALT normalisation might be less in lamivudine resistant 
patients compared to treatment naïve patients, but other studies do no report such dif-
ference. 104, 127, 128 The rate of resistance is increased in patients with lamivudine resistance 
switched to adefovir monotherapy compared to the large phase III trials and to patients 
switched to adefovir and lamivudine combination therapy. 14, 16, 103, 104, 123 Considering 
the mounting evidence of more potent antiviral effect and a lower rate of resistance 
adding adefovir to the ongoing lamivudine therapy is to be preferred above switchting 
to adefovir monotherapy. If chosen to switch to adefovir monotherapy lamivudine has 
to be continued for at least 2-3 months as this overlap may prevent the emergence of 
adefovir resistance. 103, 129
Lamivudine resistance shows some cross-resistance with entecavir in cell culture, but 
lamivudine resistant strains remain sensitive to entecavir. 130, 131 Although very effective, 
tenofovir ± 
lamivudine @
35 van Bömmel; Hepatology; 
2004 17
5.5 100 4 0
tenofovir ± 
lamivudine
44 Hann; J Hepatology; 2006 
135
4 †† 5.0 86 5
tenofovir + 
lam @
11 Van der Eijk; J Viral Hepatitis; 
2005 176 $
10 0 0 5.0 91
tenofovir @ 10 Dore; J Infect Dis; 2004 177 20 10 4.9 25
tenofovir @ 12 Núñez; Aids; 2002 178 $ 11 8 3.8 58 1
tenofovir @ 20 Nelson; Aids; 2003 179 25 4.0
tenofovir @ 12 Benhamou; NEJM; 2003 180 0 0 0 3.8
table 4. Treatment outcomes after 1 year of treatment for different antiviral drugs for the management 
of lamivudine resistant chronic hepatitis B for both HBeAg positive and HBeAg negative patients. Efficacy 
measures presented are off-treatment responses for PEG-interferon and on-treatment responses for 
nucleos(t)ide analogues.
$ results after 24 weeks of treatment
@ including HIV/HBV co-infected patients
± some patients with, some patients without combination therapy
†† after 24 months of treatment
‡ Patients with decompensated cirrhosis
1 LLD 200 copies/ml 4 LLD 400 copies/ml 7 LLD 1.0x105 copies/ml
2 LLD 300 copies/ml 5 LLD 1.0x103 copies/ml
3 LLD 366 copies/ml 6 LLD 2.0x103 copies/ml
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treatment outcomes with 1 mg entecavir in lamivudine resistant patients were less com-
pared to 0.5 mg entecavir in treatment naïve patients as viral decline (6.9 vs. 5.1 log10 
copies/ml) and rates of PCR-negativity (67 vs. 19%) were lower after 48 weeks of treat-
ment (Table 4). 13, 132 Entecavir has a high barrier to resistance as multiple mutations are 
necessary for the virus to be resistant. Lamivudine refractory patients already harbour 
some of these mutations and entecavir resistance occurs therefore more frequent in 
lamivudine resistant patients. After 1 year 1.4% of patients became resistant increasing 
up to 9% after two years and 15-19% after 3 years of treatment. 76, 132, 133
Tenofovir disoproxil fumarate possesses potent activity against lamivudine resistant 
hepatitis B (Table 4). 17, 95, 134, 135 Lamivudine resistant mutants lead to a slight 1.8-5.7 
fold increase in IC 50 values. The known mutants however remain sensitive to tenofovir 
and the mutation pattern of tenofovir has no overlap with the mutational pattern of 
lamivudine. 124, 126, 136 Most studies add tenofovir to lamivudine, though tenofovir mono-
therapy seems to be equally effective. 137 Tenofovir is thought to be a more potent viral 
suppressing agent for lamivudine resistant HBV compared to adefovir, but its efficacy 
is only investigated in relatively small groups of patients. Many of them including HIV-
HBV co-infected patients. 17, 135 Being a very promising drug, more studies have to be 
conducted to determine the exact role or the combination with other compounds for 
the treatment of lamivudine resistant hepatitis B.
Adefovir resistance
Adefovir resistant strains are susceptible to lamivudine and lamivudine can thus be used 
for rescue therapy. 138 Indeed clinically lamivudine is able to reduce the viral load in ad-
efovir resistant patients. 139, 140 The effect of adefovir associated mutations on long-term 
treatment is unknown. It is likely that lamivudine resistant strains severely limit the use 
of lamivudine. In vitro a strain conferring resistance to both adefovir and lamivudine is 
viable and has reduced sensitivity to all common drugs used for hepatitis B, although 
tenofovir and entecavir are likely to be able to suppress HBV DNA. 138 Adefovir resistant 
strains are susceptible to entecavir and tenofovir in vitro. 138, 141 In very small series teno-
fovir and entecavir proved effective against adefovir resistant HBV. 103, 142
Entecavir resistance
Entecavir resistance is highly cross-resistant with lamivudine as entecavir resistance 
requires lamivudine resistance. 130 This mutant strains are in vitro sensitive to adefovir 
and clinically treatment with adefovir resulted in decline of the viral load. 130, 143 Tenofovir 
seems also be effective in case of entecavir resistance. 106
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Future directions for the management of resistance
The development of resistance is the largest limiting factor for long-term treatment with 
nucleoside or nucleotide analogues and should therefore be studied in detail. Lamivu-
dine as well as many other L-nucleosides have high rates of resistance caused by a single 
mutation. Due to the high resistance rate and being the only oral drug available for a 
long time, it gave the opportunity to study the mechanisms and outcomes of resistance. 
The large number of patients treated with lamivudine with subsequent development 
of resistance made it possible to study the effect of salvage therapy. Entecavir and 
adefovir proved their efficacy in large populations. But despite all these opportunities 
we still do not know the exact incidence of adefovir resistance in lamivudine resistant 
patients. Although the balance tips to lamivudine and adefovir combination therapy 
over adefovir monotherapy, the definite answers has not been provided, especially the 
question whether monotherapy comes with higher rates of resistance. Tenofovir seems 
to be a very promising drug, although studies are small and little is known on the effect 
of tenofovir monotherapy on lamivudine resistant strains. Very little data is available 
on the occurrence and management of adefovir and entecavir as well as newer drugs. 
Studying resistance for compounds with low rates is difficult as large numbers have to 
be treated. Large scale initiatives are necessary to study the effectiveness and resistance. 
Understanding of mutational patterns is very important as each pattern has its own 
influence on replication fitness and cross-resistance. In vitro studies and molecular 
modelling have to provide these answers to design optimal treatment regimens. This 
approach is needed as many drugs have been developed and it is not feasible to test all 
drugs or combinations for all mutational patterns.
dIscussIon
The knowledge and therapeutic options came a long way since the discovery of the 
hepatitis B virus. Nowadays chronic hepatitis B virus infection is a treatable disease. 
However much remains unknown and treatment options are far from perfect. The 
natural history is only partially understood and only recently the importance of viral 
load has been revealed. 19-21 Further studies have to identify the factors involved in the 
progression of disease in order to be able to identify those patients in need of treatment. 
Treatment options are diverse and have limitations in tolerability and efficacy. More data 
are needed to be able to predict treatment outcome in patients. This is especially impor-
tant for the treatment with interferon, which is costly and is associated with consider-
able side effects and an overall success rate between 30-40%. However this treatment 
proved to be able to inactivate the disease for long periods in responders, which might 
result in HBsAg-seroconversion. Research to identify those patients likely to respond 
116 Chapter 7
to treatment before the start of therapy or within a few weeks after start of treatment 
is urgently needed. Nucleoside or nucleotide analogue therapy is the alternative for 
interferon based treatments and the response rates on treatment are higher compared 
to interferon. However relapse is frequent after discontinuation, while identifying those 
relapsing is not possible. This has resulted in long-term treatment, although it is known 
that response can be sustained off-treatment. By identifying the factors responsible for 
sustained response, it might be possible to accurately predict sustainability. In theory 
this could result in nucleos(t)ide analogue therapy of limited duration. This is especially 
important in young adults who often have a desire for pregnancy, whilst the antiviral 
drugs have not been investigated on safety for the unborn child, or long-term in patients 
themselves.
Data on treatment efficacy in treatment experienced patients is limited. Therefore 
large cohorts of patients have to be studied. Especially the rate of resistance and the mu-
tational patterns are hard to assess. For some therapies resistance rates are low or muta-
tional patterns are diverse. Genotypic and phenotypic testing and molecular modelling 
are helpful to determine the level of cross-resistance with other compounds. Promising 
rescue therapies should be studied clinically in order to determine their efficacy. The 
data on resistance, (mutational patterns, replication fitness, molecular modelling and 
cross resistance) is scattered and therefore it is almost impossible to look up the implica-
tions of a specific mutational pattern. A large central database combining all the data 
on resistance could provide this information and would be of great value for everyone 
interpretating mutational patterns. This database could also provide clinicians advice on 
treatment for an individual resistant patient. More specific knowledge on resistance calls 
for the development of new techniques that are sensitive, able to detect new variants, 
able to determine whether multiple variants are located on the same genome, easy to 
perform and interpreted, cheap and suitable for mass screening.
As none of the current treatments for chronic hepatitis B is optimal, prevention of 
infection should be one of the cornerstones of management of chronic hepatitis B. Safe 
and well tolerated vaccines for hepatitis B have been developed and their effectiveness 
have been proved. There have been some concerns about the luxation of autoimmune 
phenomena’s. 144 Three WHO large scale evaluations revealed no increased risk for the 
development of autoimmune diseases. 145-147
In conclusion: The management of chronic hepatitis B evolved fast and nowadays 
hepatitis B is a treatable disease, More research on the factors involved in response to 
treatment or treatment failure is needed to better tailor treatment to the individual 
patient. Much attention should be paid to universal worldwide vaccination as this may 
significantly change the burden of disease.
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Treatment options and insights have come a long way since the discovery of the hepati-
tis B virus in 1967. Numerous treatments options emerged and we have gained deeper 
insight into its epidemiology, natural history, genetics, interaction with the immune 
system and response to treatment. As a result treatment responses have improved. 
Nowadays the disease can be controlled in the majority of patients. Treatment how-
ever, is still far from ideal, as cure is achieved in only a minority of patients treated with 
interferons which, have a lot of side effects. The viral replication inhibitors have higher 
response rates and few side effects, but ideal treatment duration is not known and the 
drugs at present are continued for long periods. The safety in the long term is not known 
and the emergence of resistant strains limit their effectivity. Hepatitis B is highly adapted 
to the human body deluding the immune system in ways only partly understood. In 
addition it has the capability to maintain a very stable genetic reservoir in the form of 
covalently closed circular DNA (cccDNA) protecting the virus against eradication from 
a vigorous immune response or strong inhibition of the viral replication. This cccDNA 
can be detected even in patients with HBsAg seroconversion and forms the basis for 
viral relapse in immune compromised subjects. The replication error of the virus is 
high, wich means it can adapt to new conditions and become resistant to therapy. This 
combination of diversity of the human host and virus makes each infected individual 
unique. Initially treatment options were limited, but in recent years options have been 
expanded. New dilemmas arise with increasing understanding of the disease. In this 
thesis several of these dilemmas are discussed. PEG-interferon-α therapy seems far less 
effective in patients who are lamivudine resistant. Only 12% of patients sercoconverted 
to HBeAg negativity. In addition these patients had only faint bands in the resistance as-
say suggesting only small quantities of mutant virus were present. Although we studied 
the largest cohort described to this date, numbers are still too small to draw definite 
conclusions. However these findings support the concept that genotypic alterations 
in the viral genome and therefore viral structure which are associated with resistance 
influence the host immune response system.
Patients becoming resistant to antivirals form a new group, which is rapidly becoming 
more diverse as new drugs are marketed and new mutations develop. A complicating 
factor is cross-resistance between many of these drug, what limits the efficacy of other 
drugs. Resistance rates for nucleoside-naïve patients are very low in patients treated 
with entecavir. Resistance rates are much higher in lamivudine-resistant patients due 
to partial cross-resistance. Even long-term vigorous suppression with entecavir in lami-
vudine resistant patients does not provide complete protection against the develop-
ment of entecavir resistance. This underlines the importance of viral replication for the 
development of resistance. Tenofovir therapy proved to be highly effective in case of 
entecavir resistance.
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Changing the treatment regimen from tenofovir to adefovir in lamivudine-resistant 
patients responding to tenofovir resulted in viral relapse and 6 of 10 patients had a 
viral load above 104 copies/ml. All patients with over 103 copies/ml at the time of switch 
relapsed. This provides additional evidence for tenofovir being a stronger antiviral 
than adefovir. It also indicates that patients should not be switched from tenofovir to 
adefovir.
Outcomes of adefovir treatment in an open unselected population are poorer than 
the outcomes of randomised trials. Many patients do not achieve virological response 
and resistance rates are much higher. Patients with cirrhosis turned out to have lower 
response rates and higher rates of resistance. This group is at high risk for the develop-
ment of hepatocellular carcinoma or decompensation and viral control is therefore ex-
tremely important. Cirrhotic patients treated with adefovir require frequent monitoring. 
HBV genotype has proven to be a predictor of response to therapy in PEG-interferon-α 
treatment, but also appear to play a role in nucleoside or nucleotide treatment.
Liver transplantation is the ultimate salvage therapy for HBV infected patients. How-
ever post-transplant patients need life-long immunosuppressants and HBIg therapy to 
prevent rejection and recurrence of HBV. Patients with acute fulminant liver failure due 
to acute hepatitis B are subjected to the same schedule of immunoprohylaxis as patients 
with chronic hepatitis B. They differ however in their immune response. It seems safe to 
discontinue HBIg prophylaxis in patients transplanted for acute fulminant hepatitis B. 
This prevents potential risks of HBIg therapy and discomfort for the patients and reduces 
treatment costs substantially.
In conclusion: several factors have been identified which influence treatment outcome. 
Although the mechanisms behind these factors are only partly understood, the factors 
are of clinical significance. Both patient and viral characteristics have to be taken into ac-
count to determine the optimal treatment and follow-up tailored to the patient. Patient 
tailored treatment is feasible, but at present is far from perfect. In the forthcoming years 
new drugs will be available and more will be learned about factors influencing response. 
Old treatment schedules and new regimes need to be evaluated in different groups of 
patients. Such large scale clinical studies result in a better understanding of hepatitis B 
infection and will help optimizing patient-tailored treatment.
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Sinds de ontdekking van het hepatitis B virus in 1967 zijn de behandelingsmogelijkheden 
en inzichten zijn enorm toegenomen. Verscheidene behandelingen zijn ter beschikking 
gekomen en de kennis van de epidemiologie, natuurlijk beloop, genetica, de interactie 
met het immuunsysteem en de respons op behandeling is verruimd. Als gevolg hiervan 
zijn de behandelingsuitkomsten verbeterd. Tegenwoordig kan de ziekte bij de meeste 
patiënten onder controle worden gehouden. De ideale behandeling is nog ver weg. 
Genezing wordt slechts in een minderheid van de met interferon behandelde patiënten 
bereikt en deze behandeling gaat gepaard met de nodige bijwerkingen. De respons van 
middelen die de virale replicatie remmen ligt hoger en ze hebben weinig bijwerkingen. 
De behandelingsduur is echter onbekend en moeten derhalve gedurende lange tijd 
worden gecontinueerd. De veiligheid van deze geneesmiddelen op de lange termijn is 
onbekend. Bovendien wordt de effectiviteit aangetast door het ontstaan van resistente 
stammen.
Het hepatitis B virus heeft zich goed aangepast aan menselijk lichaam en is in staat 
het immuunsysteem te omzeilen op manieren die grotendeels onbekend zijn. Het virus 
is in staat een stabiele pool van genetisch materiaal in de vorm van covalent gesloten 
circulair DNA (cccDNA) te handhaven, welke het virus beschermd tegen irradicatie ten 
tijde van een krachtige immuunrespons of sterke onderdrukking van de virale replicatie. 
Zelfs bij patiënten met HBsAg seroconversie kan nog cccDNA worden aangetoond. Dit 
kan aanleiding geven tot terugkeer van ziekte in immuungecompromiteerde patiënten. 
Het aantal fouten tijdens replicatie is hoog, waardoor er vele virusvarianten ontstaan en 
het virus zich zo kan aanpassen aan veranderende omstandigheden en zodoende the-
rapie resistent wordt. De combinatie van grote diversiteit van de gastheer en het virus 
maakt elke infectie uniek. In vroeger tijden waren de behandelingsopties gelimiteerd, 
maar deze zijn de laatste jaren toegenomen. Nieuwe dilemma’s ontstaan met onze 
toegenomen kennis van de ziekte. In dit proefschrift worden enkele van deze dilemma’s 
besproken.
Behandeling met PEG-interferon-α lijkt minder effectief in patiënten die resistentie 
hebben ontwikkeld tegen lamivudine. Slechts 12% van de patiënten werden HBeAg 
negatief. Bovendien hadden de patiënten die HBeAg negatief werden vage bandjes in 
de resistentie bepaling wat suggereert dat er slechts een geringe hoeveelheid resistent 
virus was. Hoewel het de grootste groep die beschreven is zijn de aantallen te klein 
om een definitieve conclusie te trekken. Dit fenomeen suggereert dat veranderingen 
in het virale genoom en hiermee in de structuur van het virus die geassocieerd zijn met 
resistentie ook de immuunrespons van de gastheer kunnen beïnvloeden.
Patiënten die resistent worden vormen een nieuwe groep, welke snel diverser wordt 
doordat er nieuwe geneesmiddelen op de markt komen en er nieuwe mutaties ontstaan. 
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Een complicerende factor bij de behandeling is kruisresistentie waardoor ook de effec-
tiviteit van andere middelen beïnvloed kan worden. De incidentie van resistentie bij 
nucleoside naïeve patiënten is erg laag wanneer ze behandeling met entecavir krijgen. 
De incidentie van resistentie is veel hoger in patiënten die reeds lamivudine resistent 
zijn door gedeeltelijke kruisresistentie. Zelfs langdurige krachtige onderdrukking van de 
virale replicatie door entecavir in lamivudine resistente patiënten geeft geen volledige 
bescherming tegen het ontstaan van entecavir resistentie. Behandeling met tenofovir 
bleek zeer effectief te zijn in het geval van entecavir resistentie. Het veranderen van het 
behandelingsregime in lamivudine resistente patiënten goed reagerend op behande-
ling met tenofovir naar adefovir resulteerde in virale relapse. Na omzetten hadden 6 van 
de 10 patiënten een virale load van boven de 104 kopieën/ml. Alle patiënten met een 
virale load van meer dan 103 kopieën/ml op het moment van therapie omschakeling 
hadden een relapse. Dit is extra bewijs dat tenofovir een krachtiger antiviraal middel 
is dan adefovir. Het toont ook aan dat patiënten niet van tenofovir over gezet moeten 
worden op adefovir.
Het overtuigenste bewijs wordt geleverd door adequaat gepowerde, dubbelblind 
gerandomiseerde studies. De keerzijde van deze studies is dat dit een geselecteerde 
populatie is die geen afspiegeling van de huidige populatie hepatitis B patiënten 
is, omdat de meesten reeds behandeling in het verleden hebben gehad. Bij velen 
faalde deze behandeling, vaak ook door het ontstaan van resistentie. De uitkomsten van 
adefovir in een ongeselecteerde populatie zijn minder dan vergeleken met die van de 
gerandomiseerde trials. Velen hebben geen virologische response en de incidentie van 
resistentie is veel hoger. Vooral patiënten met levercirrhose bleken een lagere response 
op behandeling te hebben en vaker resistent te worden. Patiënten met cirrose hebben 
een hoog risico om een hepatocellulair carcinoom te krijgen of hepatologisch te decom-
penseren en virale onderdrukking is daarom zeer belangrijk in deze groep. Met adefovir 
behandelde patiënten met een levercirrose dienen nauwgezet vervolgd te worden.
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“Last, but not least” is een vaak gehoorde uitdrukking als het gaat om het dankwoord. 
En niet ten onrechte. Neem de opbouw van dissertaties. Een titelblad met de naam 
van de promovendus. Dit wordt gevolgd door een persoonlijk gekleurde visie op het 
onderwerp met hierin de doelstellingen van het proefschrift. De hoofdmoot wordt 
gevormd door de bevindingen, dikwijls in de vorm van publicaties, waarbij de promo-
vendus steevast op de eerste of tweede plaats in het rijtje van auteurs staat. Het op de 
voorgrond plaatsen van de promovendus wordt gecomplementeerd door een discussie 
van de hand door de ‘auteur’ van de dissertatie. De gemotiveerde lezer moet zich eerst 
door specialistische teksten worstelen bijna geheel in het teken van de promovendus. 
Het getuigt dikwijls van een groot doorzettingsvermogen om een proefschrift van voor 
tot achter te lezen. Pas als het boek bijna uit is ontvouwt zich het plot. De rechtlijnigheid 
en schijnbare simpliciteit maakt plaats voor een complex samenspel tussen de promo-
vendus en zijn omgeving. De plaats van de promovendus wisselt in het raderwerk en 
nieuwe verbanden worden aangegaan. In plaats van een persoonlijke prestatie is het 
een collectieve prestatie. Na het lezen van het dankwoord moet je dan de dissertatie 
in een ander licht zien. Er zou recht gedaan worden wanneer het dankwoord aan het 
begin van het proefschrift geplaatst wordt en de lezer het geheel direct in het juiste 
perspectief leest.
Zonder plezier in het werk geen motivatie en dus ook geen inspiratie of verfrissende 
ideeën. Ik heb een hele plezierige tijd gehad op de dakpoli, ook wel bekend als het 
Picasso-gebouw. Op de eerste plaats mijn kamergenoten Monica en later Madeleen 
en Martijn. Vaak hebben we elkaars vorderingen besproken onder het genot van een 
goed glas wijn. Gelukkig hadden we het niet alleen over het werk. Het senseo-apparaat 
zorgde voor de nodige toeloop en gezelligheid van de rest. Ik zou zeggen; blijf koffie 
drinken. Beste Annemiek. Dank voor alles wat je me hebt nagelaten om mee verder te 
gaan. Helaas heeft de lamivudine database een tweede promovendus overleeft.
Rob ik wil je bedanken voor alles wat je als co-promotor voor me gedaan hebt de 
afgelopen jaren. Jij was de echte moor achter dit proefschrift. Het was plezierig met je 
samen te werken. De rust die je uitstraalt en het respect dat je tegenover de mensen 
toont in combinatie met je grote deskundigheid van de hepatologie maken je tot een 
voorbeeld voor de mensen om je heen en in het bijzonder de artsen die je opleidt.
Harry hartelijk dank voor het begeleiden van mijn promotie. Hopelijk volgen er nog 
veel artikelen onder jouw leiding op hepatologisch gebied.
Met veel plezier heb ik gedurende langere tijd poli gedaan. Ondermeer door de 
geweldige ondersteuning door de poli assistenten. De service ging zelfs zover dat er 
koffie gebracht werd tijdens de drukke spreekuren. Ook hebben jullie me vaak geholpen 
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door verloren gewaande statussen weer boven water te krijgen. Hartelijk dank voor de 
gezellige samenwerking.
Zonder virologische data zou dit proefschrift niet tot stand zijn gekomen. Wegens het 
retrospectieve karakter van veel van de studies betekende dit voor de laboranten van 
de afdeling virologie een gang naar de vriezer om tussen de vele duizenden monsters 
de juiste te vinden. Gelukkig kon ik altijd weer bij jullie komen met de befaamde groene 
kaarten, waarna de uitslagen na enkele dagen beschikbaar waren.
De ontwikkeling van nucleoside en nucleotide analogen is in een stroomversnelling 
geraakt. Hiervan getuigen de grote multicenter trials die liepen tijdens mijn promotie-
onderzoek en die ik mocht begeleiden. Participeren is wellicht een beter woord, want 
er was al een goed geoliede machinerie in de vorm van de research nurses; Anneke, 
Heleen en Cocki. Zij verzorgden de gehele logistiek en deden het datamanagement van 
de door ons geïncludeerde patiënten. De hoogwaardige kwaliteit werd bevestigd door 
een officiële audit, waarbij men zeer lovend was over de gang van zaken in het Erasmus 
MC. Dames chapos en heel hartelijk bedankt voor alle gezelligheid.
Het hele proces nadat een artikel geschreven was, alsmede het regelen van het pro-
motietraject konden we met een gerust hart uit handen geven aan Marion en Margriet 
de stille krachten achter een promotie. Jullie stonden altijd klaar met raad en daad wan-
neer we jullie nodig hadden. Ook was het gezellig om weer eens te komen buurten als 
ontspanning.
Een observatie wordt op waarde getoetst door de statistiek. Gelukkig was Bettina 
altijd bereid uitleg en advies te geven over de statistiek. Ook was ze van onschatbare 
waarde bij het opzetten en bewerken van de diverse databases en het helpen bij het 
maken van berekeningen en figuren.
Mijn familie en vrienden wil ik bedanken voor de steun van de afgelopen jaren, die 
niet altijd even makkelijk waren en zeker de afgelopen 2 jaar werden gekenmerkt door 
een grote turbulentie. Dank voor jullie steun en motivatie, alsmede ook de vele hulp op 
andere gebieden.
Alle mensen die ik die tijdens mijn promotieonderzoek mijn pad gekruist hebben en 
een helpende hand hebben geboden wil ik hartelijk bedanken voor hun steun en inzet. 
Dankzij jullie allen is de wetenschap weer een klein stukje verder en ziet de toekomst 
van de patiënt met chronische hepatitis B er weer wat zonniger uit.
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De auteur van dit proefschrift werd op 9 mei 1979 geboren te Amstelveen. Van 1991 
tot 1997 volgde hij de opleiding voorbereidend wetenschappelijk onderzoek aan het 
Hermann Wesselink College te Amstelveen.
In 1997 startte hij met de studie geneeskunde aan de Erasmus Universiteit te Rot-
terdam.
Na het behalen van zijn artsexamen in 2003, begon hij als arts-onderzoeker in het 
Erasmus MC te Rotterdam aan het onderzoek over de behandeling van hepatitis B, dat 
is beschreven in dit proefschrift (supervisor Prof. Dr. S.W. Schalm, in 2006 opgevolgd 
door Prof. dr. H.L.A. Janssen. Tijdens zijn promotie-onderzoek had hij een eigen poli 
alwaar patiënten met chronische hepatitis B behandeld werden. Ook begeleidde hij de 
dagelijkse gang van zaken van enkele grote internationale multi-center studies voor 
hepatitis B in het Erasmus MC.
Van februari 2007 tot december 2007 werkte hij als arts-assistent bij de Interne Ge-
neeskunde in het Spaarne Ziekenhuis te Hoofddorp. Hierna kreeg hij een aanstelling als 
arts-assistent bij de Cardiologie in het Sint Lucas Andreas Ziekenhuis te Amsterdam. Als 
toekomstig beroep heeft hij gekozen voor de functie van bedrijfsarts.
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abbreviations
HCC hepatocellular carcinoma
HCV hepatitis C virus
HDV hepatitis Delta virus
HIV human immunodeficiency virus
HR hazard ratio
i.v. intravenous
IFN-a interferon-α
IU/l international unit/ liter
LAM lamivudine
L-dC valtorcitabine
LDD lower limit of detection
L-dT telbuvidine
L-FMAU clemuvidine
LLD lower limit of detection
MEIA microparticle enzyme immune assay
MU mega units
OLT orthotopic liver transplantation
ORF open reading frame
PCR polymerase chain reaction
PEG-interferon pegylated interferon
PMEA adefovir
qPCR quantitative polymerase chain reaction
RNA Ribonucleic acid
TDF tenofovir disoproxil fumerate
ULN upper limit of normal
ULN upper limit of normal
VR virologic response
WHO World Health Organisation
xULN times upper limit of normal
YMDD Special sequence in HBV genome (YMDD-motif )

